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Referat: 
 
Grundlage der vorgelegten Arbeit sind die bei der Alzheimerschen Erkrankung beobachtbaren 
pathologischen Merkmale, wie die progressive Akkumulation von β-Amyloid-Plaques, 
cholinerger Dysfunktion und zerebrovaskuläre Abnormalitäten. Die in englischer Sprache 
verfasste Dissertation ist eine tierexperimentelle Studie, die versucht, den Zusammenhang von 
β-Amyloid, cholinerger Neurotransmission und zerebralem Gefäßsystem bei der 
Alzheimerschen Erkrankung näher zu charakterisieren. An Hirnmaterial aus der transgenen 
Maus Tg2576, die die schwedische Mutation des humanen Amyloidpräkursorproteins als 
Transgen trägt und ab dem 10. Lebensmonat durch humane β-Amyloid-Plaqueablagerungen 
in der Hirnrinde imponiert, wurden im Altersverlauf (4 bis 18 Monate) immunhistochemische 
Untersuchungen zur morphologischen Integrität der zerebralen Mikrogefäße, der kortikalen 
cholinergen Nervterminalen und der intrazerebralen cholinergen neurovaskulären Innervation 
durchgeführt.  
 
Am somatosensorischen Kortex werden beispielhaft die Expression des Glukosetransporters 1 
oder Solanum tuberosum Lektin als Kapillarmarker und des vesikulären 
Acetylcholintransporters als Marker für cholinerge Fasern mittels Immunfluoreszenz und 
Laser-Scanning-Mikroskopie erfasst, einer semiquantitativen Computer-gestützten Bild-
analytischen Auswertung unterzogen und mit dem Ausmaß der kortikalen Plaquebeladung 
korreliert. So konnte gezeigt werden, dass die Dichte der Blutgefäße und cholinergen Fasern 
im somatosensorischen Kortex von transgenen Tieren mit dem Alter im Vergleich zu 
nichttransgenen Kontrolltieren abnimmt, was mit einer Reduktion der perivaskulären 
cholinergen Innervation einhergeht. 
Die erhobenen Befunde stützen die von J.C. de la Torre und T. Mussivand schon im Jahre 
1993 formulierte „vaskuläre Hypothese“, wonach bei der sporadischen Form der 
Alzheimerschen Erkrankung alters- und Lebensstil-bedingte Schädigungen des zerebralen 
Gefäßsystems eine zentrale Rolle bei der Manifestierung der Erkrankung spielen. 
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CHAPTER 1: INTRODUCTION 
1.1 Alzheimer's disease 
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by a progressive loss 
of memory and cognition. There are estimates that in Germany approximately 1.2 million 
people suffering from dementia with about two thirds of these individuals representing 
dementia of AD type. Because of an expanding population and increasing life expectancy, the 
number of affected individuals is projected to rise to more than 2.6 million in Germany 
(Deutsche Alzheimer Gesellschaft e.V., 2011) and ~115 million worldwide by 2050 
(Alzheimer’s Association, 2011: Wold Alzheimer report 2009, Alzheimer’s disease 
international). AD now afflicts 0.1 percent of individuals at age of 45-65 years and less than 3 
percent at age of 70-74 years in Germany (Deutsche Alzheimer Gesellschaft e.V., 2011), with 
an approximate doubling of incidence for every 5 years of age afterwards (Alzheimer’s 
Association, 2011). By the age of 80 - 84 years, the risk reaches nearly 13 percent and 
approximately two thirds of people aged 90 and older have AD in Germany (Deutsche 
Alzheimer Gesellschaft e.V., 2011).  
Two forms of AD are known: early-onset familial AD (familial form, FAD) and late-onset 
sporadic AD (sporadic form). The majority of AD is sporadic (≥ 95 percent).  
In families with an autosomal dominant early-onset AD mutations in three genes, the amyloid 
precursor protein (APP) gene on chromosome 21, the presenilin-1 (PS1) on chromosome 14, 
and the presenilin-2 (PS2) on chromosome 1, have been found. About twenty missense 
mutations in APP gene have been described (Goedert and Spillantini, 2006), while more than 
160 mutations in the presenilin genes have been identified (Goedert and Spillantini, 2006). 
Proteolytic processing of APP gives rise to the formation of β-amyloid, whereas presenilins 
are involved in the carboxy-terminal cleavage of APP (see chapter 1.2).  
In AD two major histopathological hallmarks occur such as β-amyloid plaques deposed 
extracellularly in cerebral cortical and hippocampal areas, and neurofibrillary tangles that 
occupy much of the cytoplasm of select cortical pyramidal neurons. 
 
β-Amyloid plaques 
Amyloid plaques (synonym: neuritic plaques, senile plaques) are extracellular deposits which 
are mostly composed of β-amyloid (Aβ), a proteolytic fragment of the APP, in the gray matter 
of the brain. The deposits are associated with neuronal terminals and degenerative swollen 
neuritis, and surrounded by a web of astrocytic processes and microglia cells (Glenner et al., 
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1984; Masters et al., 1985). Senile plaques are visible in light or fluorescence microscopy 
after histological staining by silver, Congo red, Thioflavin S and cresyl violet, or by 
immunohistochemical detection.  
 
Neurofibrillary tangles 
Neurofibrillary tangles, the second histopathological feature in AD, are pathological protein 
aggregates found within neurons in cases of AD (Grundke-Iqbal et al., 1986a, b; Iqbal et al., 
1989). They occupy much of select cortical pyramidal neurons and mostly consist of 
hyperphosphorylated tau, a microtubule-associated protein. The tau protein is a highly soluble 
microtubule-associated protein. In humans, these proteins are mostly found in neurons. One of 
tau's main function is to modulate the stability and flexibility of axonal microtubules, which is 
mediated by its degree of phosphorylation. Hyperphosphorylation of tau depresses its 
microtubule assembly activity and binding to microtubules (Iqbal et al., 2005). Abnormal 
hyperphosphorylated tau demonstrates a high tendency to aggregate and to form paired helical 
filaments (PHF) and straight filaments (SF), thus causing the insoluble cytoplasmic inclusions 
as observed in AD (Alonso et al., 2001). The level of hyperphosphorylated tau in AD brain is 
about 4-8-fold higher as compared in age-matched normal brains. The precise mechanism of 
tangle formation is not completely understood. One of the possibilities is that the abnormal 
hyperphosphorylation of tau might be due to conformational changes in tau in the diseased 
brain, which might make it a better substrate for phosphorylation and/or a worse substrate for 
dephosphorylation (phospho- /dephosphorylation imbalance) (Iqbal et al., 2005; Mi and 
Johnson, 2006). In the adult human brain, six tau isoforms are expressed through alternative 
splicing of a single tau gene on chromosome 17 (Goedert et al; 1989a, b). In AD all of the six 
tau isoforms contribute to the formation of PHF by hyperphosphorylation. Tau pathology is 
also seen in several other human neurodegenerative disorders, associated with degeneration 
and dementia (Delacourte, 2005).  
 
1.2 APP processing and β-amyloid production 
β-Amyloid (Aβ) is formed from the APP by subsequential proteolytic activities of the β- and 
γ-secretase. Much research has focused on understanding the mechanisms by which APP is 
processed to generate Aβ, because pathological production of Aβ has been proposed as an 
initial event in the development of AD. 
APP is a single transmembrane glycoprotein with 590-680 amino acid long extracellular N-
terminal domain, transmembrane tail with 28 amino acids and an approximately 55 amino 
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acid short intracellular cytoplasmic C-terminal tail (Kang et al., 1987; Masters and 
Beyreuther, 1987; Selkoe, 2001; Goedert and Spillantini, 2006). Nine isoforms are produced 
from a single APP gene on chromosome 21 by alternative mRNA splicing and encode 
proteins ranging from 365 to 770 amino acids. Two of these isoforms (APP365 and APP563) 
do not contain Aβ peptides. APP expression occurs ubiquitously, and the primary isoform 
varies according to cell and tissue type.  
In the nervous system, APP695 is expressed predominantly in neurons, whereas APP770 and 
APP751 are found in neuronal as well as non-neuronal cells (Golde et al., 1990; Kang and 
Muller-Hill, 1990; Koo et al., 1990; Wisniewski et al., 1997; Clippingdale et al., 2001; 
Selkoe, 2001), and additionally contain the Kunitz Protease Inhibitor (KPI) domain within 
their extracellular regions (Rohan de Silva et al., 1997; Kang et al., 1990). The levels of KPI-
containing APP isoforms (APP770, APP751) are elevated in AD brain and associated with 
increased Aβ production and deposition (Menendez-Gonzalez et al., 2005; Bordji et al., 2010; 
Zhang et al., 2011). Following brain injury, expression of the APP751/770 isoforms is 
substantially increased in astrocytes and microglial cells (Siman et al., 1989; Van Den Heuvel 
et al., 2000; Zheng and Koo, 2011). All three isoforms share the same Aβ and are thus all 
potentially amyloidogenic. The functional significance of the tissue-specific alternative 
splicing of APP is still not understood. 
APP is synthesized in the endoplasmic reticulum and transported through the Golgi apparatus 
to the trans-Golgi-network (Greenfield et al., 1999) where the highest concentration of APP is 
found in neurons. Then APP can be delivered in secretory vesicles to the cell surface where it 
is recycled via an endosomal-lysosomal pathway of degradation (Nordstedt et al., 1993; 
Caporaso et al., 1994), or may undergo a cleavage by the α-secretase pathway. Cell culture 
studies have suggested that most Aβ (1–40) /Aβ (1–42) is generated in the endosomal 
recycling pathway and the minority of Aβ (1–40) /Aβ (1–42) is produced in the secretory 
pathway, within the endoplasmic reticulum and Golgi apparatus (Haass et al., 1993a,b; 
Selkoe, 2001). 
Picomolar and nanomolar concentrations of Aβ peptides are found constitutively in normal 
brain (Haass et al., 1992; Seubert et al., 1993; Kar et al., 2004). The normal physiological 
function of APP is currently unknown, although in neurons it has been demonstrated to be 
localized in synapses where it may play a role in extension of neuronal terminals and 
synaptogenesis. It has been suggested that APP demonstrates neurotrophic (Jaffar et al., 2001) 
and neuroprotective (Zhang, 2004) functions, as well as may play a role in neuronal migration 
and transcellular adhesion (Zheng and Koo, 2006). The APP intracellular domain contributes 
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to protein trafficking, metabolism, and presumably exerts signaling functions as a cell surface 
receptor (Zheng and Koo, 2011). Therefore, the effect of full-length APP on cellular activity 
may represent a composition of its cleavage products, depending on the ratio of APP 
metabolites generated (Zheng and Koo, 2011; Zhang et al., 2011). APP processing and Aβ 
generation are modulated by neuronal electrical activity (Nitsch et al., 1993; Kamenetz et al., 
2003) and it has been proposed that Aβ-related peptides may act as a modulator of cholinergic 
function under normal conditions (Blusztajn and Berse, 2000; Hellstrom-Lindahl, 2000; 
Jhamandas et al., 2001; Kar, 2002; Dolezal and Kasparova, 2003; Wang et al., 2007). 
 
 
Fig. 1:  Processing of amyloid precursor protein (APP) by α-, β- and γ-secretase:  
A – amyloidogenic pathway; B – non-amyloidogenic pathway 
For more details, see description in the text.  
 
APP can be cleaved by three proteolytic enzymatic activities termed α-, β-, and γ-secretase 
(Fig. 1). The α-secretase, a member of the ADAM (a disintegrin and metalloproteinase) 
family, represents a transmembrane zinc metalloproteinase, and is active at the cell surface 
(Sisodia, 1992; Roberts et al., 1994; Zhang et al., 2011). The α-secretase activity cleaves APP 
within the Aβ-sequence (between residues 16 and 17) releasing a large soluble ectodomain, 
the N-terminal sAPPα, and a P3-CT fragment. The P3-CT fragment is subsequently cleaved 
by γ-secretase into P3, and the CT fragment. Thus, the α-secretory pathway precludes Aβ (1-
40/42) formation (Clippingdale et al., 2001; Selkoe, 2001). Non-neuronal cells preferentially 
process APP via α- and γ-secretase cleavage to generate sAPPα and the non-amyloidogenic 
membrane
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fragment P3. Thus, non-neuronal cells are not a significant source of Aβ under normal 
conditions. However, neurons do not heavily rely on this pathway and produce very low 
levels of P3 (Chyung et al., 1997). sAPPα plays an important role in neuronal plasticity / 
survival, demonstrates neuroprotective properties against excitotoxicity, regulates neural stem 
cell proliferation and is important for early CNS development, implying that most of APP’s 
physiological function is mediated by sAPPα (Zhang et al., 2011). 
Alternatively, APP can be cleaved by β-secretase pathway, which results in the formation of 
Aβ peptide, is mediated by the sequential actions of β-secretase (β-site APP cleaving enzyme, 
[BACE]) and γ-secretase enzymes). BACE1 is a membrane-bound aspartyl protease with a 
characteristic type I transmembrane domain near the C-terminus (Sinha et al., 1999; Vassar et 
al., 1999). Overexpressed BACE1 is mainly found in the Golgi endosomes and in the 
endosomes that provide an acidic environment in various cell lines (Zhang et al., 2011), 
BACE1 can be found also at the cell surface (Vassar et al., 1999; Walter et al., 2001; Huse et 
al., 2000; Huse et al., 2002). BACE2 is a homolog of BACE1 and cleaves substrates similar to 
BACE1, but its expression in neurons is basically lower than BACE1 (Bennett BD. et al., 
2000). Interestingly, cellular BACE2 cleaves APP near the α-secretase site much more 
efficiently than at the β-secretase site, but do not exclude a potential contribution of BACE2 
towards AD pathogenesis (Yan et al., 2001; Zhang et al., 2011). It was reported that sAPPβ 
can have function as a death receptor and mediate axonal pruning and neuronal cell death 
(Nikolaev et al., 2009). In addition to BACE1/ BACE2, cathepsin B has been proposed as a 
supplementary β-secretase (Zhang et al., 2011; Zheng and Koo, 2011). The β-secretase 
cleavage generates a truncated soluble sAPPβ and a membrane bound Aβ-containing C-
terminal fragment. Further proteolysis of the C-terminal fragment by γ-secretase yields the 
Aβ peptide (Esch et al., 1990; Wisniewski et al., 1997; Vassar et al., 1999; Clippingdale et al., 
2001; Selkoe, 2001). 
Aβ is also produced under normal conditions and secreted in the brain as a soluble peptide, 
which raised the possibility that Aβ may also play a physiological role. Aβ appears to be a 
normal product of cellular metabolism throughout life and circulated in human biological 
fluids (Haass et al., 1992; Seubert et al., 1992; Shoji et al., 1992). 
 
1.3 Cholinergic dysfunction in Alzheimer’s disease 
For more than 30 years, studies of the brains of those with advanced age and AD have 
consistently found damage or abnormalities in the cholinergic pathways that appeared to 
correlate well with the level of cognitive decline. Studies on aged individuals and AD 
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patients, as well as animal experiments suggest that many of cholinergic abnormalities 
including alterations in choline transport, acetylcholine release, nicotinic and muscarinic 
receptor expression, neurotrophic support, and axonal transport may all contribute to 
cognitive abnormalities in aging and AD. This has led to the formulation of the ″cholinergic 
hypothesis of memory dysfunction in senescence and in AD″ (Bartus et al., 1982; Coyle et al., 
1983), which essentially states that a loss of cholinergic function in the central nervous system 
contributes significantly to the cognitive decline. However, it is interesting to note, that 
cognitive deficits are detectable not earlier before at least 30% of total cholinergic basal 
forebrain cells have degenerated (for review, see, Schliebs and Arendt, 2006). This indicates a 
high capacity of the basal forebrain cholinergic system with regard to respond to neuronal 
degeneration. The selective cell loss in the nucleus basalis of Meynert (Whitehouse et al. 
1981; Arendt et al. 1983) and severe neurofibrillary degenerations are associated with a 
dramatic loss of cholinergic input in many areas of the cerebral cortex (Geula and Mesulam 
1989, Geula and Mesulam 1999; Mesulam, 2004). This cholinergic loss tends to correlate 
with the severity of the dementia (Perry et al. 1981; Francis et al. 1985) and with the classic 
neuropathological lesions such as neuritic plaques (Arendt et al. 1985). However, it is not yet 
clear whether the extensive loss of neurons and pre-synaptic terminals observed in AD is one 
of the primary features of this disease, or the consequences of the Aβ-pathology, or, for 
example, cerebrovascular dysfunction (see 1.4). 
The progression of dementia is associated with reductions in a number of cortical cholinergic 
markers such as acetylcholine (ACh) content (Richter et al. 1980) and release (Nilsson et al. 
1986), choline acetyltransferase (ChAT) activity (Bowen et al. 1976; Davies and Maloney, 
1976), choline uptake (Rylett et al. 1983), activity of acetylcholinesterase (AChE) (Perry et al. 
1978; Hammond et al. 1988). The later studies revealed a significant loss of nicotinic ACh 
receptors (Whithouse et al., 1986; Nordberg et al., 1986; Flynn and Mash, 1986; Nordberg, 
1992; Perry et al., 1995) and select types of muscarinic ACh receptors (Katayama et al. 1990; 
Levey, 1996; Shiozaki et al. 2001; Mash et al.1985) in the cortical and hippocampal regions 
of AD brains. This was further supported by in vivo measurements of cholinergic receptor 
expression by positron emission tomography (PET) at different stages of AD, demonstrating 
receptor abnormalities that change with disease progression (Nordberg, 2001). Teaktong et al., 
found a selective increase in α7nAChR on astrocytes of AD brain, which has been suggested 
to play a role in Aβ mediated inflammatory processes in AD (Teaktong et al., 2003; Yu et al., 
2005).  
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In contrast to observations in early-onset and aged AD cases, in patients with mild cognitive 
impairment (MCI, a prodromal stage of AD), and early forms of AD, no obvious basal 
forebrain cholinergic cell loss could be oberserved. Instead, mismatches in the expression of 
NGF, its precursor proNGF, both high and low NGF receptors, trkA and p75NTR, as well as 
changes in acetylcholine release, high-affinity choline uptake, alterations in muscarinic and 
nicotinic acetylcholine receptor expression have been detected, suggesting a loss of 
cholinergic function rather than cell death. These findings encourage the suggestion of an 
outstanding role of the cholinergic system in the functional processes that lead to AD. 
Malfunction of the cholinergic system may be solved pharmacologically by intervening in 
cholinergic as well as neurotrophic signaling cascades that have been shown to ameliorate the 
cholinergic deficit at early stages of the disease, and slow-down the progression (see, e.g. the 
review, Schliebs and Arendt, 2011). 
Whereas in the brains of AD patients no tau mutations have been observed, pathogenic 
mutations in the tau genes cause frontotemporal dementia (Goedert and Jakes, 2005) 
suggesting that post-transcriptional alterations in tau gene expression may contribute to the 
cognitive deficits in AD presumably also by interacting with the cholinergic transmission. 
Several studies have demonstrated that activation of nAChRs results in a significant increase 
in tau phosphorylation, whereas mAChR activation may prevent tau phosphorylation 
(Hellström-Lindahl, 2000; Hellström-Lindahl et al., 2000; Wang et al., 2003; for reviews see: 
Buckingham et al., 2009; Bencherif and Lippiello, 2010). Nicotine was found to stimulate tau 
phosphorylation at those sites that were also hyperphosphorylated in AD, obviously induced 
through activation of the α7 subtype of nAChRs (Wang et al., 2003). This finding was further 
substantiated by observations in triple transgenic 3xTg-AD mice which develop age- and 
regional dependent accumulation of both plaques and tangles as well as progressive deficits in 
cognition (Oddo et al., 2003; Billings et al., 2005; Kitazawa et al., 2005). Chronic nicotine 
administration to one-month-old 3xTg-AD mice for five months did not change soluble Aβ 
protein levels but showed increases of phosphorylation and aggregation of tau, which 
appeared to be mediated by p38-MAPK (Oddo et al., 2005). Additionally, Aβ has relevant 
dual neuromodulatory effects on α7 and α4β2 nicotinic receptors, controlling the release of 
glutamate, aspartate and GABA, depending upon the concentration used (Mura et al., 2012). 
Interestingly, single cell gene expression profiling revealed a shift in the ratio of three-tandem 
repeat tau to four-tandem repeat tau in individual human cholinergic basal forebrain neurons 
within the nucleus basalis and CA1 hippocampal neurons during the progression of AD 
(Ginsberg et al., 2006). The meaning of it, however, awaits further elucidation. 
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1.4 Cerebrovascular abnormalities in Alzheimer's disease 
There is a large body of evidence that neural activity is closely related to cerebral blood flow 
(CBF) (see for review Iadecola, 2004; Girouard and Iadecola, 2006). In several brain 
pathologies, the interaction between neural activity and cerebral blood vessels is disrupted, 
and the resulting homeostatic unbalance may contribute to brain dysfunction. Disruption of 
the regulation of the cerebral circulation deprives the brain of vital control mechanisms that 
ensure delivery of adequate amounts of substrate and control the homeostasis of the 
microenvironment in which the brain cells function. These alterations impair the ability of the 
brain to maintain CBF when the cerebral blood supply is compromised, exacerbating 
ischaemia and presumably promoting cognitive impairment. A growing body of evidence 
indicates that cerebrovascular dysfunctions and structural alterations occur differentially 
during normal ageing with pronounced effects in AD (Kalaria, 2009). 
Cerebrovascular pathologies such as cerebral amyloid angiopathy and endothelial 
degeneration have been reported in many AD cases (de la Torre, 2002; Kalaria, 2000; Soffer, 
2006; Thomas et al., 1996). Functional vascular abnormalties are one of the earlier clinical 
manifestations in AD (see, e.g., Farkas and Luiten, 2001), ischemic stroke increases the risk 
of the disorder (Kalaria, 2000; Kokmen et al., 1996; Snowdon et al., 1997), and the 
pathological hallmarks of AD and vascular ischemic changes have been found to coexist in 
more than 40 percent  of elderly demented individuals (Jellinger, 2007; Jellinger, 2008). 
Currently, a growing number of epidemiological, clinical, pathological, and neuroimaging 
studies revealed a distinct association between vascular risk factors and AD (Milionis et al., 
2008; Rocchi et al., 2009; Kalaria, 2009; de la Torre, 2010; Dickstein et al., 2010; Humpel 
2011).  
Structure and function of the neurovascular unit have been observed to be profoundly 
damaged in AD (Iadecola, 2004; Bell and Zlokovic, 2009; Humpel, 2011). Indeed, 
cerebrovascular abnormalities such as thickening of the microvascular basement membranes, 
decreased luminal diameter, reduction in number of cerebral capillaries, microvascular 
degeneration and diminished glucose transport across the blood-brain barrier have frequently 
been observed in Alzheimer patients (Mancardi et al., 1980 Kalaria and Pax, 1995; Kalaria 
and Hedera, 1995; Vinters et al., 1996, Claudio, 1996; Ellis et al., 1996; Farkas and Luiten, 
2001; Drzezga et al., 2003; Hunt et al., 2007; Mosconi et al., 2010; Nicolakakis and Hamel, 
2011), and the compromised cerebral hemodynamics in AD has been suggested to be 
associated with vascular oxidative stress (Faraci, 2006; Simpson et al., 2010) and 
inflammation (Paris et al., 2003). 
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Pathology of the blood brain barrier (BBB) is an early finding in white matter lesions 
associated with AD, and altered function of BBB transport may also have an impact on the 
accumulation of Aβ in the brain (Kalaria, 1992; Zlokovic, 2008; Farrall and Wardlaw, 2009). 
Serum inflammatory protein levels may alter the BBB endothelial tight junctions or actual 
transport mechanisms across the BBB, enough to allow amyloid or its precursors to leak out 
(Farrall and Wardlaw, 2009). The increased BBB permeability in AD may exacerbate further 
loss of BBB integrity thus escalating the cycle of Aβ protein accumulation and BBB damage 
(Farrall and Wardlaw, 2009). The downregulation of the BBB receptors LRP-1 (lipoprotein 
receptor related protein 1) and P-glycoprotein also may induce vascular deposition of Aβ 
(Bell et al., 2009). 
A causal relationship between vascular mechanisms and the development of sporadic AD has 
already been hypothesized in the 1990s of the last century (de la Torre and Mussivand, 1993), 
suggesting that sporadic AD may represent a vascular disorder caused by impaired cerebral 
perfusion (for reviews, see de la Torre, 2008; Isingrini et al., 2009; Iadecola, 2010; Humpel, 
2011). Indeed, during the last decades, a vast number of studies have been accumulated 
providing strong clinical and experimental evidence of an important role of vascular 
mechanisms in the development and progression of sporadic AD, which will be discussed in 
more detail in chapter 4.1. 
 
1.5 Cholinergic innervation of intracortical cerebral microvessels 
Neuronal terminals are closely associated with cerebral blood vessels. Pial arteries at the 
surface of the brain are densely innervated by perivascular nerves that originate from 
autonomic and sensory ganglia (″extrinsic nerves″) and contain many vasodilators (NO, 
acetylcholine, vasoactive intestinal polypeptide (VIP), calcitonin gene-related peptide 
(CGRP), substance P and cholecystokinin neurokinin A) and vasoconstrictors (noradrenaline, 
neuropeptide Y (NPY) and serotonin) (Hamel, 2006). Intracerebral arterioles and capillaries 
(microcirculations vessels) are innervated by ″intrinsic nerves″ that originate from subcortical 
neuronal centers as well as from local cortical interneurons (see Fig. 2). These axons contain 
many neurotransmitters, as the extrinsic nerves (Hamel, 2006; Van Beek and Claassen, 2011). 
Cortical microvessels receive a cholinergic input that originates primarily from basal forebrain 
neurons which, upon electrical or chemical stimulation, induce significant increases in cortical 
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Fig. 2: Schematic presentation of different types of perivascular cholinergic innervation of intracerebral     
           microvessels, modified after Hamel, 2006. For more details, see description in the text.  
 
perfusion together with a dilation of intracortical microvessels. Physiological evidence 
indicates that central cholinergic pathways are involved in the regulation of CBF (Biesold et 
al., 1989; Lacombe et al., 1989; Kurosawa M. et al., 1989; Hamel, 2004). The involvement of 
ACh as a neurotransmitter in the control of regional CBF was demonstrated by the 
administration of cholinergic drugs, such as blockers of mAChR, which decreased CBF and 
ACh-esterase inhibitors, which led to increased CBF (see for review Farkas and Luiten, 
2001). 
In vivo and in vitro studies have shown that intracortical microvessels dilated in response to 
stimulation with ACh (Thomas et al., 1997; Elhusseiny and Hamel, 2000). This response is 
dependent on nitric oxide (NO) production, and mediated by muscarinic receptor activation 
(mAChR), presumably through the M5-mAChR sybtype (Elhusseiny and Hamel, 2000). 
Basalo-cortical perivascular nerve terminals were detected by light and electron microscopic 
immunocytochemistry of anterogradely transported Phaseolus vulgaris leucoagglutinin (PHA-
L) following its injection in the basal forebrain (substantia innominata), and were compared to 
cortical perivascular cholinergic (immunoreactive for choline acetyltransferase (ChAT)) 
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terminals. It was established that cholinergic neurons project not only to the cortical 
neuropile, but also to the arterioles and capillaries within the cerebral cortex (Vaucher and 
Hamel, 1995).  
Cholinergic afferents also project to intracortical neurons that synthesize vasodilatators NO 
and vasoactive intestinal peptide (VIP) (Vaucher et al., 1997; Cauli et al., 2004). These 
correspond to distinct sub-population of GABA interneurons which were found to send 
numerous projections to local microvessels (Estrada and DeFelipe, 1998). Basal forebrain 
cholinergic fibers can directly affect the cortical microvascular bed, but further suggest that 
specific population of GABA interneurons could serve as a functional relay to adapt perfusion 
to locally increased neuronal activity. GABA interneurons translate incoming neuronal signals 
from various sub-cortical afferents into adapted local neuronal and vascular responses, 
including those originating from basal forebrain cholinergic neurons (Kawaguchi, 1997; Cauli 
et al., 2004; Hamel, 2004). Cortical microvessels are endowed with heterogeneous mAChRs 
(Grammas et al., 1983; Luiten et al., 1996; Elhusseiny et al., 1999). Immunohistological 
studies indicate that the total intensity of mAChR decreases along the vascular tree from large 
conducting vessels to capillaries (Badaut et al., 1997). ECs cultures from arterioles and 
capillaries of human brain expressed M1, M2 and M5 receptors; SMCs have all subtypes 
except the M4-mAChR; perivascular astrocytes have all five mAChR (Elhusseiny et al., 
1999). Binding sites for mAChR were also found in cultured retinal pericytes (Ferrari-Dileo et 
al., 1991). 
 
In conclusion, cholinergic dysfunctions of the basal forebrain as observed in AD may also 
contribute to the cerebrovascular abnormalities in a large portion of AD patients. To study this 
aspect of AD in more detail, appropriate animal models of AD are required.  
 
1.6 Transgenic Tg2576 mouse model of Alzheimer's disease 
The understanding that mutations in three genes (APP, PS1 and PS2) are directly associated 
with early onset AD and enhanced Aβ formation has provided a powerful rationale for 
studying pathogenetic aspects of AD in vivo by creating transgenic animals carrying these 
mutations.  
Over the past few years a variety of transgenic mouse lines that overexpressed mutant APP, 
PS1 or both APP and PS1 as transgenes have been developed and extensively examined (see 
for review Games, 2006).  
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One of the most widely used transgenic mice in the AD field represents the Tg2576 mouse 
developed by Karen Hsiao and co-workers in 1996. This mouse overexpresses the Swedish 
double mutation of the hAPP695 (hAPP695 K670N/M671L), that favours the formation of the 
Aβ peptide (Hsiao et al., 1996). Transgenic APP levels in the brain are 5-6 fold higher as 
compared to the endogenous mouse APP (Hsiao, 1998). Aging related increases in the levels 
of soluble and insoluble fibrillar Aβ (1-40) and Aβ (1-42) as well as the ratio of Aβ (1-42)/Aβ 
(1-40) have been found in Tg2576 mouse (Hsiao et al., 1996; Apelt et al., 2004). In Tg2576 
mice Aβ (1-42) is most abundant in plaques, whereas Aβ (1-40) predominantes in vessels 
(Kawarabayashi et al., 2001). In addition, this model develops cerebral amyloid angiopathy 
from 10 months onwards  (Hsiao, 1998; Calhoun et al., 1999; Christie et al., 2001; Robbins et 
al., 2006), while a profound alteration in the regulation of the cerebral blood circulation 
occurs already at 2–3 months of age (Niwa et al., 2000a and 2002a; Iadecola, 2004). In the old 
Tg2576 mice reduction in CBF is associated with corresponding reductions in cerebral 
glucose uptake and activity of enzymes of brain glycolysis (Niwa et al., 2002b; Bigl et al., 
2003).  
From the age of 3 months onwards these mice demonstrate cognitive deficits (King et al., 
1999). However, the most behavioural and memory abnormalities such as hippocampally-
mediated spatial memory tasks (different maze tests, contextual fear learning, operant 
learning) and non-spatial memory tasks (auditory startle, eye blink conditioning, object 
recognition), deficits in working memory retention and non-memory sensorimotor 
perturbations (hyperactivity, reductions in open field activity, disturbed sleep and wake 
patterns) have been observed in Tg2576 mice at the age of 5 to 6 months (for review, see 
Games et al., 2006). Cognitive deficits in Tg2576 mice correlate to impaired hippocampal 
long-term potentiation, and these disturbances are accompanied by minimal or no loss of 
presynaptic or postsynaptic structural elements in the hippocampus (Chapman et al., 1999). 
Moreover, elecrophysiological investigations revealed age-related impairments in basal 
synaptic transmission in hippocampus of transgenic Tg2576 mice (Fitzjohn et al., 2001).  
Analysis of the cholinergic system revealed subtle and differential changes in cholinergic 
synaptic markers in aged transgenic Tg2576 mice (Gau et al., 2002; Apelt et al., 2002; 
Klingner et al., 2003) as well as degeneration of ChAT-immunoreactive fibres in the 
environment of β-amyloid plaques and activated glial cells by means of ultrastructural 
investigations (Aucoin et al., 2005; Tomidokoro et al., 2000; Cha et al., 2001; Hernandez et 
al., 2001; Lüth et al., 2003). While no significant differences in size, shape or immunostaining 
profile of cholinergic neurons in the basal forebrain of Tg2576 mice were reported 
INTRODUCTION                                                                                                       13
(Tomidokoro et al., 2000; Apelt et al., 2002; Wong et al., 1999), an increased p75NTR protein 
level in medial septal cholinergic neurons were observed in 12-month old Tg2576 mice (Jaffar 
et al., 2001). 
Quantitation of [3H]hemicholinium-3 (HCh-3) binding to high-affinity choline uptake sites 
has been used as a marker to detect loss of cortical cholinergic fibres. Transgenic mice with 
no significant plaque load demonstrated reduced HCh-3 binding to choline uptake sites in 
anterior brain regions as compared to nontransgenic littermates, while in aged transgenic mice 
with high number of plaque deposits decreased HCh-3 binding levels were accompanied by 
increased vesicular acetylcholine transporter binding in selected cortical brain regions (Wong 
et al., 1999; Hernandez et al., 2001; Klingner et al., 2003). Receptor binding studies reported 
either no change in mAChR binding sites in the brain of Tg2576 mice (Cha et al. 2001; 
Bednar et al., 2002), or a reduction in M1- and M2- mAChR binding sites in some neocortical 
regions in aged animals (Apelt et al., 2002). Further, an age-related increase in α7 nAChR 
expression were observed in Tg2576 mouse brain (Dineley et al., 2001; Bednar et al., 2002), 
which have been suggested to play a role in Aβ mediated inflammatory processes (Teaktong 
et al., 2003; Yu bet al., 2005). In aged transgenic mice GABAA-, NMDA, AMPA, kainate, 
and beta-adrenergic as well 5-HT1A- and 5-HT2A-receptor binding levels were hardly affected, 
whereas α1- and α2-adrenoceptor binding was increased in selected cerebral cortical regions 
as compared to non-transgenic littermates (Klingner et al., 2003). 
The development of changes in both cholinergic and non-cholinergic markers in transgenic 
Tg2576 mouse brain already before the onset of progressive plaque deposition provides in 
vivo evidence of a modulatory role of soluble β-amyloid on cortical neurotransmission and 
may be referred to the deficits in learning and memory observed in these mice also before 
significant plaque load.  
Aβ depositions in transgenic Tg2576 mouse brain have been shown to induce micro- and 
astrogliosis which is accompanied by the induction of both pro- and anti-inflammatory 
cytokines (Irizarry et al., 1997; Frautschy et al., 1998; Benzing et al., 1999; Apelt and 
Schliebs, 2001). Astrocytes were found in close proximity to both fibrillary and diffuse Aβ 
deposits and were detectable at very early stages of plaque development, while activated 
microglia appeared in and around fibrillary Aβ plaques only. 
Markers of oxidative stress as well as of the antioxidant defense enzymes heme-oxygenase 
and superoxide dismutase were increased in these transgenic animals (Hsiao, 1998). Apelt et 
al. demonstrated that the activities of superoxide dismutase and glutathione peroxidase in 
cortical tissue from Tg2576 mice steadily increased from postnatal age 9–12 months; the 
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levels of cortical nitric oxide, and reactive nitrogen species demonstrated peak values around 
9 months of age (Apelt at al., 2004). 
 
1.7 Aim of study 
As outlined in the Introduction part, a large number of AD patients demonstrate 
cerebrovascular pathology such as cerebral amyloid angiopathy, microvascular degeneration, 
and impaired vascular regulation coupled with impaired glucose metabolism in cholinoceptive 
target regions. These pathological changes are accompanied by the occurrence of dysfunctions 
in cortical cholinergic neurotransmission, an early and consistent feature of AD. Therefore, 
the question arises of whether changes in cerebral vessels, cortical cholinergic denervation, 
and β-amyloid formation and deposition are interrelated. 
The present study intends to contribute to the following questions: 
 
1) Do cholinergic and vascular dysfunctions interact with each other, i. e. cortical cholinergic 
dysfunction affects the vascular system and/or vice versa.  
2) Does the formation and deposition Aβ–peptides during aging interact with the cholinergic 
innervation of cerebral cortical blood microvessels. 
 
To in vivo characterize the developmental relationship of amyloid formation and deposition, 
cortical cholinergic innervation and cerebrovascular abnormalities, transgenic Tg2576 mice 
that express the Swedish double mutation of human APP and progressively develop 
Alzheimer’s-like amyloid deposits were considered as an appropriate in vivo animal model. 
Serial cortical cryocut sections, obtained from mice at ages ranging between 4 and 18 months, 
were subjected to immunohistochemistry to label vascular endothelial cells, cortical 
cholinergic nerve terminals and β-amyloid plaques, followed by a thorough quantitative 
evaluation of the age-related spatial relationship between cerebral cortical capillaries, amyloid 
plaques and cholinergic terminals, using computer-assisted imaging analysis. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Chemical reagents used 
Alkylphenylpolyethylenglycol (Triton X-100) (FERAK Laborat GmbH; Berlin Germany); 
Cresylviolet; 3,3'-Diaminobenzidine Tetrahydrochloride (DAB) (Sigma-ALDRICH, Inc; St. 
Louis, USA); Di-sodiumhydrogenphosphate Dihydrate (Na2HPO4.2H2O; M=177.99) (Carl 
Roth GmbH, Karlsruhe, Germany); Ethanol (C2H5OH M= 46,07); Entellan (Merck, 
Darmstadt, Germany); Formic acid; 85% solution (HCOOH; M= 46,03) (VEB Jenapharm-
Laborchemie APOIDA, Germany); Nickel Ammonium Sulphate (II) Hexahydrate 
(Ni(NH4)2(SO4)2x6H2O; M=395) (Merck, Darmstadt, Germany); Hydrogen Peroxide, 30% 
solution (H2O2); Paraformaldehyde (HO.(CH2O)n.H) (VEB LABORCHEMIE APOLDA, 
Germany); Sucrose (C12H22O11; M=342.30) (Carl Roth GmbH, Karlsruhe, Germany); Sodium 
Azide (NaN3; M= 65.01); Sodium Chloride (NaCl; M= 58.442) (Carl Roth GmbH, Karlsruhe, 
Germany); Sodium Dihydrogenphosphate Monohydrate (NaH2PO4.H2O; M=138) (Carl Roth 
GmbH, Karlsruhe, Germany); Thioflavin S (Sigma Chemical Co; St. Louis, USA); Tris 
(C4H11NO3; M=121.14) (Carl Roth GmbH, Karlsruhe, Germany). 
 
2.1.2 Biological reagents used 
Biotinylated horseradish peroxidase (Bio-HRP); Bovine serum albumin (BSA) (SERVA 
Electrophoresis GmbH, Heidelberg, Germany); Heparin Sodium (Hofmann-La Roche AG, 
Grenzach-Wyhlen, Germany); Normal Goat Serum (GNS), Donkey Normal Serum (DNS) 
(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA); Streptavidin (native 
protein) (Molecular Probes, Inc, Eugene, USA).  
 
2.1.3 Preparation of solutions and buffers 
Perfusion buffer: 
 Quantity Final concentration 
NaCl 9.0 g 0.9% 
Heparin Sodium 5000 IE (1.0 ml) 5000 IE/l 
Ad 1 liter of bidistilled water.  
 
Phosphate buffer (PB): 
 Quantity Final concentration 
Na2HPO4.2H2O 17.8 g/l 0.1 M 
NaH2PO4.1H2O 13.8 g/l 0.1 M 
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adjust to pH value of 7.4 
 
Fixative: 
 Quantity Final concentration 
Paraformaldehyde 40.0 g/l 4 % 
Ad 1 liter of 0.1 M PB-buffer pH 7.4. 
 
Postfixation solution: 
 Quantity Final concentration 
Sucrose                  300.0 g 30% 
NaN3                   0.5 g  0.05% 
Ad 1 liter of 0.1 M PB-buffer, pH 7.4. 
 
Tris-buffered saline (TBS buffer): 
 Quantity Final concentration 
Tris 12.14 g 0.1 M 
NaCI 8.77 g 0.15 M 
Ad 1 liter of bidistilled water. Adjust pH to 7.4 with HCl. 
 
Tris-buffered saline with bovine serum albumin (TBS-BSA buffer): 
 Quantity Final concentration 
Bovine serum albumin (BSA) 2 g 2% 
Ad 100 ml of 0.1 M TBS buffer, pH 7.4 
 
Avidin–biotin-peroxidase complex (ABC): 
 Stock solution of reagents Final concentration 
Streptavidin  1mg/ml 12.5 μg/ml 
Biotinylated horseradish 
peroxidase (Bio-HRP) 0.5 mg/ml 2.5 μg/ml 
Reagents were dissolved in 1.0 ml of 0.1 M TBS, pH 7.4, containing 2% bovine serum 
albumin, under steadily stirring at room temperature for 45 minutes allowing to form the 
ABC complex.  
 
DAB-Nickel buffer (buffer for immunoperoxidase labeling): 
 Quantity Final concentration 
Tris 6.057 g 0.05 M 
Ad 1 litre of bidistilled water. Adjust pH to 8.0 with HCl. 
 
DAB-Nickel staining solution: 
 Quantity Final concentration 
Ni(NH4)2(SO4)2 x 6 H2O 0.04 g 0.4% 
DAB 0.002 g 0.02% 
H2O2  30% 5 μl 0.015% 
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Ad 10 ml of 0.05 M DAB-Nickel buffer, pH 8.0. 
 
1% Thioflavin S staining solution: 
Thioflavin S ......................................... - 0.05 g 
Bidistilled water .................................. - 5.0 ml 
3% Cresyl violet solution: 
Cresyl violet ........................................ - 3.0 g  
Bidistilled water .................................. - 100.0 ml 
Nissl staining solution: 
Cresyl violet 3% .................................. - 5.0 ml 
Sodium acetate 0.1 N .......................... - 8.0 ml 
Acetic Acid 0.1 N ................................ - 92.0 ml 
Dehydration solutions for Nissl staining: 
Solution Content 
No. 1 Ethanol 70% 
No. 2 Ethanol 80% 
No. 3 Ethanol 85% 
No. 4 Ethanol 95% 
No. 5 Ethanol 100% 
 
2.1.4 Antibodies and reagents used for immunohistochemistry 
In Table 1 all antibodies, both primary and secondary, used in this study for 
immunohistochemistry, are listed including their specificities, manufacturer, and the final 
concentration at which the particular antibody was applied for immunostaining, while in 
Table 2 the most important reagents for histochemistry are summarized.  
 
Table 1: Antibodies used for immunohistochemical staining. 
Antibody Specificity Manufacturer Final dilution /concentration 
Primer antibodies    
GLUT1 
Polyclonal Rabbit Anti-
Glucose Transporter 1 
(Rat)  
Rat (mouse) CALBIOCHEM- 
NOVABIOCHEM 
International, Inc.;  
catalog No 400055 
 
1:3000 
VAChT 
Polyclonal Rabbit Anti-
Vesicular Acetylcholine 
Transporter (Rat) Serum 
Rat (mouse) Phoenix Pharmaceuticals, 
Inc., Belmont, USA.; 
catalog No H-V006; 
lot No 420206 
 
 
1:500 
ChAT  
Polyclonal Goat anti-
Choline acetyltransferase 
Avian, Chicken, 
Guinea Pig, Human, 
Mouse, Monkey, 
Rat, Opposum. 
CHEMICON®
International, Inc.; 
catalog No AB 144 P; 
lot No 22090335 
1:25 
20µg/ml 
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NeuN 
Monoclonal Mouse Anti-
Neuronal Nuclei IgG1, 
clone P19  
Mouse, rat, human, 
chick, salamander 
 
CHEMICON® 
International, Inc.; 
catalog No MAB377; 
lot number 25070259 
 
1:100 
10 μg/ml 
4G8 
Biotinylated monoclonal 
Mouse Anti-Human 
Amyloid-Beta Protein IgG, 
isotype IgG2b;  
clone 4G8  
Human, mouse 
 
SIGNET Laboratories, 
Inc; Dedham 
Massachusetts, USA. 
catalog No 9240-02   
1:1000 
1 μg/ml 
GFAP 
Polyclonal Rabbit Anti- 
Cow glial fibrillary acidic 
protein 
Human, mouse, rat, 
sheep, cow, cat, dog 
DAKO, A/S Denmark; 
catalog No MAB 3418; 
lot No 096(701) 
1:1000 
CD11b 
Monoclonal rat anti mouse 
CD11b Protein, 
isotype IgG2b; 
clone 5C6 
Mouse, rat SEROTEC Ltd., 
Oxford,England; 
catalog No MCA711 
1:1000 
1:100 
Secondary antibodies    
Polyclonal Biotin-SP-
conjugated AffiniPure 
Goat Anti-Rabbit IgG  
Human, mouse, rat Jackson ImmunoResearch 
Laboratories, Inc.; West 
Grove, PA, USA. 
catalog No 11-065-144  
1:500 
2 μg/ml 
Polyclonal Cy TM3-
conjugated Affini Pure Goat
Anti-Rabbit IgG (H+L) 
Rabbit; 
minimal cross-
reaction to human, 
mouse and rat serum 
proteins 
Jackson ImmunoResearch 
Laboratories, Inc.; 
catalog No 111-165-144; 
lot No 67223 
1:75 
20 μg/ml 
Polyclonal CyTM2-
conjugated AffiniPure 
Goat Anti-Mouse IgG 
Mouse;  
minimal cross-
reaction to rat, 
human, bovine and 
horse serum 
proteins; 
Jackson ImmunoResearch 
Laboratories, Inc.; 
catalog No 115-225-100; 
lot No 47110 
1:50 
26 μg/ml 
Polyclonal CyTM3-
conjugated AffiniPure 
Goat Anti-Mouse IgG 
(H+L) 
Mouse; 
Minimal cross-
reaction to rat, 
human, bovine, 
horse and rabbit 
serum proteins 
Jackson ImmunoResearch 
Laboratories, Inc.; 
catalog No ;115-165-166 
lot No 68848 
1:300 
(5 μg/ml) 
Polyclonal CyTM2-
conjugated AffiniPure 
Donkey anti-Goat  
IgG (H+L) 
Goat; 
Minimal cross-
reaction to chicken, 
guinea pig, Syrian 
hamster, horse, 
human, mouse and 
rat serum proteins 
Jackson ImmunoResearch 
Laboratories, Inc.; 
catalog No 705-225-147 ;  
lot No 57922 
20 μg/ml 
Polyclonal CyTM5-
conjugated AffiniPure 
Goat Anti-Mouse IgG 
Mouse Jackson ImmunoResearch 
Laboratories, Inc. 
20 μg/ml 
Polyclonal CyTM5-
conjugated AffiniPure 
Goat Anti-Rabbit IgG  
Rabitt Jackson ImmunoResearch 
Laboratories, Inc. 
20 μg/ml 
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Table 2: List of reagents, used for histological staining. 
Reagent Manufacturer Final concentration 
Biotinylated-Solanum Tuberosum (Potato
Lectin 
Vector Laboratories, Inc., 
Burlingame, USA; 
Catalog No.B-1165; Lot No.Q0923 
30 μg/ml 
Streptavidin, Cyanine, CyTM2 conjugated purchased from  Dianova, Hamburg 20 µg/ml 
Streptavidin, Cyanine, CyTM3 conjugated purchased from  Dianova, Hamburg 20 µg/ml 
Thioflavin S Sigma Chemical Co,  St. Louis, USA 1% 
Cresylviolet  3% 
 
2.1.5 Transgenic animals 
The transgenic mice used in this study contained the human APP695 with the double mutation 
(K670N, M671L), which was found in a la rge Swedish family with early onset of 
Alzheimer's disease, inserted into a hamster prior protein (PrP) cosmid vector in which the 
PrP open reading frame was replaced by that for the variant APP (Tg(HuAPP695,K670N-
M671L)2576), as developed and described previously by Hsiao et al. (Hsiao et al., 1996; 
Hsiao, 1998). The transgene is expressed in C57B6/SJL F1 mice (kindly provided by Dr. 
Karen Hsiao, University of Minnesota), backcrossed to C57B6 breeders. N2 generation mice 
were studied at ages of 4, 6, 8, 10, 12, 18 months (n=3-5; see Table 3). Age-matched non-
transgenic littermates served as controls. The transgenity was determined in 2-month-old 
animals in tail biopsy material by PCR (Hsiao et al., 1996), and further cross-checked after 
sacrifice. 
The animals were housed in a 12h light-dark cycle, with ad libitum access to food and water 
under the care of the Animal House of the Leipzig Medical Faculty (Medizinisch-
Experimentelles Zentrum) according to the guidelines of Animal Care of the European Union. 
 
Table 3: List of animal experimental groups studied including size of group (no of mice). 
 4 month 6 month 8 month 10 month 12 month 18 month 
Tg2576 3 3 2 3 3 5 
Wild Type 3 3 2 2 4 5 
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2.2 Methods 
2.2.1 Tissue preparation and sampling of sections 
Mice were deeply anaesthesized by an overdose of CO2 and transcardially perfused with the 
perfusion buffer (50 ml) followed by the fixative (50 ml, for composition, see 2.1.3). Brains 
were removed from the skull and post-fixed in the same fixative overnight (for 24 h) at room 
temperature. After cryoprotection of the tissue by equilibrating in 30% sucrose in PB buffer, 
series of coronal sections were cut at 30 μm thickness on a freezing microtome (Leica, 
Heidelberg, Germany) and collected in 0.1 M TBS, pH 7.4, with 0.005% sodium azide as 
additive. 
 
2.2.2. Immunohistochemistry 
Depending on the properties of the secondary antibody used to visualize the 
immunoreactivity, either by fluorescent or non-fluorescent dyes, different staining protocols 
were applied as described below. 
 
2.2.2.1 Protocol of immunofluorescent labeling: 
1. Free-floating brain slices were washed in 0.1 M TBS pH 7.4, three times for 10 
minutes. 
2. Non-specific binding sites in the tissue were blocked with either 5% normal goat 
(GNS) or donkey serum (DNS) and 0.3% Triton X-100 in TBS (GNS / DNS-T-TBS) 
for one hour. 
3. After blocking sections were incubated overnight at room temperature with either 
GNS-T-TBS or DNS -T-TBS containing the particular primary antibody of interest 
(see, Table 1). 
4. Washing out the unbound primary antibody with TBS, pH 7.4, three times for 10 
minutes. 
5. Incubation of slices for one hour at room temperature with the appropriate Cy-
conjugated secondary antibody (see, Table 1), prepared in TBS containing 2% bovine 
serum albumin (TBS-BSA) and used at concentrations as stated in Table 1. 
6. To wash out the unbound secondary antibody, sections were treated three times for 10 
min with TBS, briefly dipped in distilled water, mounted on fluorescence-free slides, 
air-dried and coverslipped with Entellan.  
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2.2.2.2 Protocol of  immunoperoxidase labeling (ABC technique): 
1. Free-floating sections were washed in 0.1 M TBS, pH 7.4, three times for 10 minutes. 
2. To remove endogenous peroxidase activity sections were incubated for 30 min in TBS 
containing 0.6% hydrogen peroxide. 
3. To wash out remaining hydrogen peroxide slices were bathed in 0.1 M TBS, pH 7.4, 
three times for 10 minutes. 
4. After blocking of non-specific binding sites in the tissue either with GNS-T-TBS or 
DNS-T-TBS for one hour, sections were further incubated overnight at room 
temperature with either GNS-T-TBS or DNS -T-TBS containing the particular 
primary antibody of interest (see, Table 1). 
5. Washing out the unbound primary antibody with TBS, pH 7.4, three times for 10 
minutes. 
6. Incubation of slices for one hour at room temperature with the appropriate biotinylated 
secondary antibody (see, Table 1), prepared in TBS-BSA and used at concentrations 
as stated in Table 1. 
7. To wash out the unbound secondary antibody, sections were treated three times for 10 
min with TBS, pH 7.4, followed by incubation with avidin-biotin-peroxidase complex 
(ABC) at room temperature for one hour. 
8. Sections were rinsed in 0.1 M TBS, pH 7.4, twice for 10 minutes, and once in 0.05 M 
Tris-buffer, pH 8.0, for 10 minutes.  
9. For visualization of the immunoreactivity, sections were shortly preincubated in 
0.05M Tris-buffer, pH 8.0, containing 0.02% 3,3´-diaminobenzidine 
tetrahydrochloride (DAB) and 0.4% nickel–ammonium sulphate (II) hexahydrate 
(Tris-DAB-Nickel), followed by further incubation for x min in Tris-DAB-Nickel 
solution additionally containing 0.015% hydrogen peroxide. 
10. To wash out non-reacted dye, sections were treated for 10 min in 0.05 M Tris-buffer, 
pH 8.0, and twice for 10 min in 0.1 M TBS, pH 7.4. 
11. Finally, sections were briefly dipped in distilled water mounted onto gelatine-coated 
glass slides, air-dried and coverslipped with Entellan. 
 
Immunolabeling of sections by omission of primary antibodies were considered as control in 
both protocols.  
 
 
 
 
MATERIALS AND METHODS                                                                                                               22 
2.2.2.3 Combination of primary and secondary antibodies 
In Table 4 the primary antibodies used in this study are listed together with the secondary 
antibodies applied to visualize the immunoreactivity including the antigen that should be 
detected in the brain tissue.  
 
Table 4:  Combinations of primary and secondary antibodies used to visualize a particular 
  immunoreactivity including the cellular markers to be detected in brain tissue. 
 
Primary antibody Secondary antibody Visualization of 
immunoreactivity 
Detection of 
GLUT1  
Polyclonal Rabbit Anti-
Glucose Transporter 1 
(rat, mouse) antibody 
Biotin-SP-conjugated 
AffiniPure Goat Anti-Rabbit 
IgG 
or 
Polyclonal Cy TM3-
conjugated AffiniPure Goat 
Anti-Rabbit IgG (H+L) 
DAB-Ni 
or 
fluorescent 
staining 
Vascular endothelial 
cells/ brain vessels 
 
VAChT 
Polyclonal Rabbit Anti-
Vesicular Acetylcholine 
Transporter (rat, mouse) 
Serum 
Polyclonal Biotin-SP-
conjugated AffiniPure Goat 
Anti-Rabbit IgG 
or 
Polyclonal Cy TM3-
conjugated AffiniPure Goat 
Anti-Rabbit IgG (H+L) 
DAB-Ni 
or 
fluorescent 
staining 
Cortical cholinergic 
terminals and 
extracortical 
cholinergic neurons 
NeuN 
Monoclonal Mouse 
Anti-Neuronal Nuclei 
antibody 
Polyclonal CyTM2-conjugated 
AffiniPure Goat Anti-Mouse 
IgG 
or 
Polyclonal CyTM5-conjugated 
AffiniPure Goat Anti-Mouse 
IgG 
fluorescent 
staining 
Neuronal body 
ChAT  
Polyclonal Goat  
anti-Choline 
acetyltransferase 
Polyclonal CyTM2-conjugated 
AffiniPure Donkey anti-Goat 
IgG 
fluorescent 
staining 
Cortical cholinergic 
terminals and 
extracortical 
cholinergic neurons 
4G8 
Biotinylated monoclonal 
Mouse Anti-Human 
(Mouse) Amyloid Beta 
Protein antibody 
Polyclonal CyTM3-conjugated 
AffiniPure Goat Anti-Mouse 
IgG 
fluorescent 
staining 
Neuritic (senile) and 
diffuse plaque  
(total plaque load) 
CD11b (Mac-1) 
Monoclonal Rat Anti-
Mouse CD11b 
Polyclonal CyTM3-conjugated 
AffiniPure Goat Anti-Rat 
IgG 
fluorescent 
staining 
Microglia 
GFAP 
Polyclonal Rabbit Anti- 
Cow glial fibrillary 
acidic protein 
Polyclonal CyTM5-conjugated 
AffiniPure Goat Anti-Rabbit  
IgG 
fluorescent 
staining 
Astroglia 
(GFAP-positive 
macroglia) 
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2.2.2.4 Protocol of  β-amyloid immunolabeling (Formic acid epitope retrieval method): 
To break the protein cross-links of β-amyloid and to unmask the antigens, a pretreatment of 
brain sections by formic acid is recommended to enhance staining intensity (Kitamoto et al., 
1987). 
 
1. Free-floating sections were washed in 0.1 M TBS, pH 7.4, three times for 10 minutes. 
2. Incuibation of brain sections with 85% formic acid for 10 minutes at room 
temperature. 
3. To wash out the formic acid, slices were bathed in 0.1 M TBS, pH 7.4, three times for 
10 minutes. 
 
For immunofluorescent detection of β-amyloid, steps 2 - 6 of the protocol of 
immunofluorescent labeling (2.2.2.1) were applied, while for visualization β-amyloid by the 
ABC technique, steps 2 -11 of the protocol of immunoperoxidase staining (2.2.2.2) were used.  
 
2.2.3 Histochemistry 
2.2.3.1 Thioflavin S staining 
Fluorescence labeling of β-amyloid by Thioflavin S was performed after DAB-Nickel 
immunochistochemical staining of brain vessels with GLUT1 antibody in order to 
demonstrate fibrillary β-amyloid (senile plaque) in the brain tissue sections of mice. 
Immunolabeling was also performed to establish co-localisation of total β-amyloid loading 
(immunohistochemistry with 4G8 antibody) and fibrillay component of β-amyloid deposits 
(Thioflavin S-positive aggregates). For this reason the brain sections were covered with 1 % 
Thioflavin S solution for 20 minutes in darkness, followed by washing the slides for one 
minute with bidistilled water, and by immersion into 80% ethanol for 40 minutes. Finally the 
slides were washed two times with bidistilled water, air-dried, and coverslipped with Entellan.  
 
2.2.3.2 Nissl staining  
Nissl staining (cresyl violet) was used to stain all neuronal (partially glial cells) cell bodies in 
a particular brain section. Sections were immersed in Nissl staining buffer for 30 minutes, 
followed by rinsing in bidistilled water. The slices were dehydrated by bathing in a series of 
ethanol solutions with increasing concentrations (70 – 100%), air-dried and coverslipped with 
Entellan. 
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2.2.3.3 Solanum Tuberosum Lectin (STL) staining 
Solanum tuberosum lectin (STL) was used to label cerebral blood vessels. For STL labeling 
sections were washed in 0.1 M TBS pH 7.4 and preincubated with 5% normal goat serum and 
0.3 %Triton x-100 in TBS (NGS-T-TBS) for one hour by room temperature. Sections were 
incubated in a cocktail of antibody and biotinylated Solanum tuberosum lectin (dilution 30 
μg/ml) in NGS-T-TBS overnight by room temperature (see, Table 5). Afterwards, sections 
were extensively rinsed in TBS and incubated with a mixture of carbocyanine (Cy)-
conjugated secondary antibodies (accordingly to primary antibodies) and Cy2-conjugated 
Streptavidin (dilution 20 μg/ml) (for visualisation of reactivity from lectin) in TBS with 2% 
BSA (TBS-BSA) for one hour at room temperature. Finally, section were rinsed in TBS and 
in distilled water, mounted onto slides, dried and coverslipped with Entellan.  
 
2.2.4 Double and triple-coloured immuno- / histochemical  
 staining of brain sections 
To check for cellular co-localization of selected protein markers, brain sections were 
subjected to subsequent staining with particular antibodies and/or dyes, as listed in Table 5.  
 
Table 5:  Cocktails used for double and triple staining of antigens  
  in one and the same brain section. 
 
 Cocktail of antibodies/dyes Tissue markers to be detected Type of staining 
1 Anti-GLUT1 
Thioflavin S 
Brain vessels and fibrillar β-amyloid 
load (neuritic plaque) 
Double staining 
 
2 Anti-GLUT1 
Solanum Tuberosum Lectin 
Co-localisation of staining from brain 
vessels;  
by transgenic mice β-amyloid load 
(Potato Lectin) 
Double staining 
 
3 Anti-VAChT 
Anti-ChAT 
Co-localisation of cortical cholinergic 
terminals 
Double staining 
 
4 Anti-VAChT 
Anti-NeuN 
Cortical cholinergic terminals and 
neuronal cells in the cortex 
Double staining 
 
5 Anti-VAChT 
Anti-NeuN 
Solanum Tuberosum Lectin 
Cortical cholinergic terminals, neuronal 
cells body β-amyloid load and vessels 
Triple staining 
6 4G8* 
Thioflavin S 
Co-localisation of total β-amyloid and 
fibrillar β-amyloid 
Double staining 
 
7 Solanum Tuberosum Lectin 
Thioflavin S 
Co-localisation of blood vessels and β-
amyloid plaque 
Double staining 
8 Solanum Tuberosum Lectin 
Thioflavin S 
4G8* 
β-amyloid plaque labeling by three 
markers 
Triple staining 
9 Solanum Tuberosum Lectin 
CD11b (Mac-1) 
Co-localisation of microglia and blood 
vessel 
Double staining 
10 Solanum Tuberosum Lectin Co-localisation of β-amyloid plaque Triple staining 
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4G8** 
Anti-GFAP 
markers (Solanum Tuberosum Lectin 
and 4G8**) and GFAP positive 
macroglial cells  
 
*no formic acid pretreatment; **with formic acid pretreatment (see 2.2.2.4) 
 
2.2.5 Microscopy and digital image processing  
The DAB-stained brain sections were analysed using a Zeiss Axioplan – Axio Vision two light 
microscope including a Sony DXC-930P colour video camera system. A microscope equipped 
with a ×2.5, ×10, ×20 without immersion plan achromatic objectives and a ×10 projection 
lens was used. Double-labeled sections (DAB-Nickel and Thioflavin S) were investigated 
using a double light (fluorescents and normal light) microscopy. 
Immunofluorescent preparations were examined with a Zeiss LSM 510 Confocal Laser 
Scanning Microscope Axioplan 2. A microscope equipped with a ×40 water immersion and 
×100 oil immersion plan achromatic objectives and a ×10 projection lens was used. Confocal 
images of Cy2 fluorescence were obtained with the Argon laser (488 nm) and emission band-
pass filter (BP) 505-550. The Helium-Neon laser (543 nm) and emission filter BP 560-615 
were used to detect Cy3 fluorescence. The second Helium-Neon Laser (633 nm) and emission 
long-pass filter (LP) 650 was used for Cy5 fluorescence detection. In case of triple 
immunohistochemistry, Cy5-labeled structures were color-coded in blue. The slides 
histochemical labelled with Thioflavin S were examined using the Argon laser (488 nm) and 
emission filter BP 505-550. To avoid overlap in the excitation spectrum of the different 
fluoroprobes a separate track and channel was used for each laser. Multi-slice imaging was 
obtained by optical sectioning of the stained tissue with confocal laser scanning microscope. 
In this manner, appointed volume was systematically scanned across an x-y plane, and 
through multiple z planes. The deep-tissue volume scans produced images from slice 
thickness of 0.98 µm. 
Adobe Photoshop 5.0 software (Adobe Systems, Mountain View, CA) was used to process the 
original images with minimal alterations to the background (brightness and contrast).  
 
2.2.6 Morphological and morphometric analyses 
2.2.6.1 Cortical microvessels 
The amount of immunostained capillaries was semiquantitatively estimated from the area 
covered by GLUT1-immunoreactivity (as corresponding reaction product) and referred to the 
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total area of the corresponding cerebral cortical region, using a video camera-based, computer 
assisted imaging device and the software package of Imaging Research Inc., MCID 4.0. 
Thresholds for object segmentation (of reaction product) were established in standard slides 
and remained constant throughout the analysis session. Regions routinously analyzed 
comprised parietal cortex (bregma –1.46–1.58): barrel field in somatosensory cortex 1 
(S1BF). Capillary density was defined as percentage of the area covered by GLUT1-
immunoreactivity as compared to the total area of a distinct cerebral cortical region. Densities 
of brain capillaries were estimated either in the vicinity of plaques (capillaries located within 
a circle with varying diameter, see Figs. 2.1) or in distinct cortical layers (see Figs. 2.2). To 
analyze the laminar distribution of capillaries, the cerebral cortex was subdivided into boxes 
of 200µm x 50µm from layer I to VI (Figs. 2.2), and the capillary density in each box was 
graphed against cortical depth. Cortical layers were differentiated by Nissl staining of 
subsequent sections. 
For analysising the spatial relationship between cerebral cortical capillaries and amyloid 
plaques brain sections double stained for both brain capillaries and β-amyloid plaques were 
used. Around a particular β-amyloid plaque circles with increasing diameters were drawn 
(Figs. 2.1), and the vessel density per circle area estimated as described above. This procedure 
allows to estimate the capillary density against the distance from senile plaques. 
 
a
A    
b
B  
Fig. 2.1: Brain sections double stained for both GLUT1-immunoreactivity (labeled in black) and for β-amyloid 
(green fluorescence (core region appears white)), were used to estimate the capillary density against the distance 
from senile plaques. Circles with increasing diameter were drawn around the plaque core (white), and the density 
of capillaries per particular circle area is determined. Scale bar 100 µm. 
 
A. GLUT1-immunoreactivity (highlighted in red colour) detected in circle a.  
B. GLUT1-immunoreactivity (highlighted in red colour) detected in circle b.  
 
With increasing distance from the plaque core GLUT1-immunoreactivity inhances.  
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A   B  
Fig. 2.2: To analyse the laminar distribution of capillaries, the cerebral cortex was subdivided into boxes of  
200µm × 50µm from layer I to layer VI, and the capillary density in each box was graphed against cortical depth.  
Scale bar 200 µm. 
 
2.2.6.2 Cortical cholinergic innervation 
2.2.6.2.1 Total density of VAChT-immunoreactivity 
The cholinergic innervation was studied in brain slices containing the barrel field area of 
somatosensory cortex (bregma -1.70-1.82mm, according to the brain atlas of Franklin and 
Paxinois, 1997), subjected to immunohistochemistry to label VAChT. Photomicrographs of 
the immunostained sections were obtained using a confocal laser scanning microscope 
equipped with a ×40 water immersion plan achromatic objective and zoom mode 0.7 (final 
magnification 28x). A total of four random of depth scans (one photomicrograph on each side 
from two adjacent sections per mouse) were taken from each of the following layers: I, II-III 
(taken together), IV, V, VI. The delimitation of individual cortical layers was based on known 
morphological criterias visualized in sections counterstained for NeuN (see Figs. 2.3). 
The total VAChT-immunopositive labeling (comprising varicosities and cholinergic fibers) 
was analysed using the software package Soft Imaging System analySIS® (Soft imaging 
system GmbH, Muenster, Germany), particularly designed for color grain counting. The area 
occupied by VAChT-immunoreactivity (VAChT-IR) was measured in each cortical layer, 
corrected for background staining by setting a detection threshold, referred to the total area of 
the respective layer, and expressed as percentage of VAChT-immunoreactivity of total area of 
each layer.  
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Fig. 2.3: Representative images of coronal mouse brain slices obtained at bregma -1.70 mm with schematic 
drawings of the cortical layers selected (red and blue frameworks) for semiquantification of the cortical cholinergic 
fibre networks (VAChT-IR) of barrel field area in the somatosensory cortex (S1BF) (A). The photomicrographs of 
VAChT-immunostaining (B) were obtained by laser scanning microscopy (LSM 510, Zeiss). Five adjacent fields 
were used to sample cortical layers I-VI within the hemisphere in each section. Illustration of the analytical 
protocols used to determine total VAChT-IR (B red fluorescence, D) in each layer of cortex (F) using the software 
package Adobo Photoshop 5.0 and Soft Imaging System analySIS® according NeuN staining (B blue, C, E). 
Scale bar 50 μm. 
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2.2.6.2.2 Estimation of the density of varicosities on cholinergic fibres 
Brain sections were immunostained for VAChT-immunoreactive cholinergic fibres as 
described above. Using the software package Adobo Photoshop 5.0 and Soft Imaging System 
analySIS®, the total length of fibres of a selected area was measured, and the total number of 
varicosities pertinent to VAChT-immunoreactive fibres was counted. The ratio of total length 
of fibres and the total number of varicosities per section allowed to calculate a “mean distance 
between varicosities” on cholinergic terminals of a particular area (see Figs. 2.4).  
 
A
 
B
 
C
 
Fig. 2.4: Representative example to demonstrate the estimation of the density of varicosities on cholinergic fibres. 
Laser scanning micrographs of brain sections (A) imunostained for VAChT-immunoreactive cholinergic fibres (red 
fluorescence) were used to estimate the length of cholinergic fibres (B, indicated by yellow lines), and the number 
of varicosities (C, indicated by yellow dots) using the software package Adobo Photoshop 5.0 and Soft Imaging 
System analySIS®, as indicated by yellow drawings. The ratio of total length of fibres and the total number of 
varicosities per section was calculated and used as an entity to estimate the mean distance between varicosities 
on cholinergic terminals of the area shown.  
 
2.2.6.3 Estimation of cholinergic perivascular innervation of cortical microvessels 
Brain sections double-stained for VAChT and STL were used to characterize cholinergic 
innervation of cerebral cortical microvessels. Using the image software package analySIS®, 
the length of microvessels and number of perivascular VAChT-positive terminals in close 
vicinity (within a distance of 3 µm) of vessel basal lamina were estimated in laser scanning 
micrographs of brain sections, immunohistochemically stained for VAChT- immunoreactive 
cholinergic fibres and STL-positive cerebral cortical vessels, as representatively demonstrated 
in Figs. 2.5. The number of perivascular VAChT terminals in close vicinity to the vessel 
basement membrane (≤3 µm), counted in a fixed area of individual cortical layers (I, II-III, 
IV, V and VI) of S1BF, were related to the corresponding total length of vessels present in the 
same area. The data expressed as ratio of number of cholinergic terminal endings located 
within a 3-µm-distance range from the cortical vessels basal lamina to the total length of 
microvessel, represent the “mean contacts/endings per 100 µm length of blood vessel” 
assessed in a particular cortical area. 
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A  B  C  
Fig. 2.5: Representative examples to demonstrate estimation of cholinergic perivascular innervation of cortical 
microvessels. Laser scanning micrographs of brain sections (A), double immunohistochemically stained for 
VAChT (red fluorescence) and STL (green fluorescence), were used to estimate length of microvessels (B, 
indicated by yellow lines) and number of endings of perivascular VAChT-positive terminals in close vicinity (≤3 
µm) to the vessel basal lamina (C, indicated by yellow dots) by means of the image software package analySIS® 
as indicated by yellow drawings. 
 
2.2.6.4 Three-dimensional-imaging of vessels innervation 
The three-dimensional image processing was used to visualize the morphological parameters 
of perivascular cholinergic terminals (VAChT-positive) projecting to brain capillaries and 
larger vessels.  
A series of 2D images were collected through the whole thickness of a particular brain section 
(z-level) by Laser Scanning microscopy, and later assembled to provide a 3D image (see also 
2.2.5). 
 
2.2.7 Statistical analysis  
The corresponding data obtained from animals in each experimental group were averaged, 
and the corresponding standard deviations calculated. Differences between parameters 
quantitatively assessed in this study were tested using one-way analysis of variance 
(ANOVA), followed by a Student’s t-test analysis. 
The Kolmogorov-Smirnov test was applied to test the sample distribution against a normal 
distribution. All calculations were performed with SPSS software (version: 11.5 and 14.0).  
P < 0.05 was considered to be statistically significant.  
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CHAPTER 3: RESULTS 
Using a transgenic animal approach the effect of aging-related β-amyloid deposition on 
cerebral cortical blood vessels, and their cholinergic innervation was studied by means of 
morphometric analyses of brain sections immunostained for brain vessel, cholinergic nerve 
terminals, and β-amyloid. 
 
3.1 Developmental and amyloid plaque-related changes in cerebral  
 cortical capillaries in transgenic Tg2576 Alzheimer mice 
3.1.1 Morphological distribution of brain vessels in the 
  cerebral cortex of wild type mice 
To reveal the distribution of blood capillaries in the mouse brain during postnatal 
development, cryocut sections throughout the brain obtained from mice at ages ranging 
between 4 and 18 months, were immunostained to label the glucose transporter type 1 
(GLUT1), which is used as a marker of vascular endothelial cells. 
Representative images of immunostained section from normal adult mice are presented in 
Figs. 3.1, demonstrating a region-dependent distribution of GLUT1-immunoreactivity with 
higher densities of brain capillaries in cerebral cortical regions such as motor and 
somatosensory cortices as well as hippocampus, while in order brain regions including 
pirifom cortex, striatum, thalamic areas, and corpus callosum, a somewhat lower 
immunostaining for vascular endothelial cells was observed. 
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Fig. 3.1 A-F: Representative examples of immunohistochemistry to label the glucose transporter GLUT1, a 
marker of vascular endothelial cells, in brain sections of a 8-month-old transgenic mouse (A), including 
hippocampus (B), somatosensory cortex (C), piriform cortex (D), corpus striatum (E) and thalamic area (F). 
Scale bars: A, 800 μm; B-D, 200 μm; E-F, 100 μm. 
 
Moreover, in most cerebral cortical areas, the distribution of brain capillaries demonstrated a 
laminar pattern as representatively shown for the somatosensory cortex in Fig. 3.2. 
Densitometric evaluation of GLUT1-immunoreactivity over all layers of the somatosensory 
cortex revealed somewhat higher densities of brain vessels in cortical layers III, IV and V 
(Fig. 3.3). 
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Fig. 3.3: Densitometric analysis of GLUT1-immunostaining throughout the layers of the somatosensory cortex 
from a 18-month-old non-transgenic mouse brain. The laminar pattern demonstrates a cortical layer-specific 
distribution of brain capillaries in the the somatosensory cortex.  
Data are given as percentage of capillary load per area and represent the mean ± S.E.M. obtained from 
assessments of sections from three animals. 
 
3.1.2 Microvessel density under plaque burden 
To reveal whether deposition of amyloid plaques may effect cerebral cortical blood supply or 
blood-brain barrier, a quantitative analysis of the spatial relationship between cerebral cortical 
capillaries and amyloid plaques was performed using dual immunohistochemistry to label 
both brain capillaries and β-amyloid plaques. Cortical cryocut sections, obtained from 
transgenic Tg2576 mice that overexpess the Swedish double mutation of human amyloid 
precursor protein and progressively develop Alzheimer-like β-amyloid deposits at ages of 10 
month onwards, were immunostained with anti-GLUT1 antibody and counterstained with 
Thioflavin S. The combination of light and fluorescence microscopy revealed different 
Fig. 3.2: A representative example for 
GLUT1 immunostaining in the 
somatosensory cortex of 10-month-old 
non-transgenic mouse is given, clearly 
demonstrating the laminar distribution 
pattern of brain vessels. 
Scale bar: 200 μm. 
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distribution patterns of brain capillaries around senile plaques, as shown in Fig. 3.4. Around 
large senile plaques the capillary density was lower and the size of vessels appeared smaller 
as compared to those located more distal, while diffuse plaques demonstrated a close 
association of capillaries with no signs of any damage Fig. 3.4). 
 
  
  
  
 
Cortical brain sections from 18-month-old transgenic Tg2576 mice which demonstrate a high 
plaque load, were immunostained for GLUT1 and counterstained with Thioflavin S, and used 
Fig. 3.4 A-E: Representative photomicrographs 
(A-E) from double stained brain slices for 
GLUT1 (DAB with nickel, black stain) and β-
amyloid (Thioflavin S, green fluorescence) 
demonstrating differential distributions of blood 
vessels around β-amyloid plaques. 
Scale bar: 50 µm.
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to estimate the the densities of brain capillaries around large senile plaques (≥ 50 µm in 
diameter). Applying quantitative computer-assisted image analysis (for methodological 
details, see 2.2.6), the GLUT1-immunoreactivity was determined in dependence on the 
distance from the plaque core. As graphed in Fig. 3.5, the capillary density in the vicinity of 
senile plaques is lower by about 60% as compared to that detected more distal from the 
plaque core. 
 
 
    
 
 
Fig. 3.5: Plot of density of capillaries against their distance from senile plaques which are larger in size by more 
than 50 µm. Data are given as percentage of capillary load per area and represent the mean ± S.E.M. of five 
animals. Friedman Test, * P ≤0.05, **P ≤ 0.01 vs. value detected at a distance of 60 µm. 
Inserts: A, B representative image of a large Thioflavin S-positive senile plaque (white lesion) in parietal 
somatosensory cortex of 18-month-old transgenic mice. Scale bar: 100 µm. 
 
Furthermore, cerebral brain vessel distribution in cortical areas with low plaque load was 
compared with that demonstrating a high plaque burden. In the somatosensory cortex of 18-
month-old Tg2576 mice with high plaque deposits, the density of brain vessels was 
significantly lower as compared to neighboured areas with low plaque burden. This effect was 
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mainly observed in cortical layer IV (Fig. 3.6). The capillary density in low plaque areas of 
the somotaosensory cortex did not significantly differ from that estimated in non-transgenic, 
wild type mice (Fig. 3.6). 
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Fig. 3.6A: Comparison of laminar density distribution of brain capillaries in cortical areas with high (black 
columns) and low (white columns) β-amyloid plaque load. Immunostaining for GLUT1 was evaluated in the 
somatosensory cortex of 18-month-old transgenic mice. Data are given as percentage of capillary load per area 
and represent the mean ± S.E.M. of five animals. ** P < 0.001 vs. corresponding control value, two-tailed 
Student's t-test.  
 
  
 
In Tg2576 mouse brain, cortical levels of soluble β-amyloid steadily increase with age, but 
significant deposition of fibrillar, senile β-amyloid plaques in cortical areas does not occur 
before postnatal age of 10 month (Apelt et al., 2004). To reveal whether already the 
accumulation of soluble β-amyloid during early postnatal life may have consequences on the 
brain capillary system, the density of brain vessels estimated in selected cortical regions from 
transgenic Tg2576 at ages ranging between 4 and 18 months was compared with that 
observed in non-transgenic littermates.  
Fig. 3.6B: Representative brain section used for 
estimation of capillary densities in areas with high and 
low plaque load (white colour staining).  
Scale bar: 200 μm. 
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In the somatosensory cortex of non-transgenic mice the capillary density steadily increased 
with age between 4 and 10 months, reaching the highest level at the age of 10 month and 
persisting up to the age of 18 months (Fig. 3.7). 
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Fig. 3.7: Comparison of the developmental 
pattern of capillary densities estimated in 
cortical layers (I, II-III, IV, V and VI) of the 
somatosensory cortex of transgenic Tg2576 
(black squares) mice and non-transgenic 
littermates (grey triangles) at ages ranging 
between 4 and 18 months.  
Data are given as percentage of capillary load 
per area and represent the mean ± S.D. of 
three to five animals in each group of age. 
*P ≤0.05 vs. control value, two-tailed 
Student's t-test. 
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The developmental profile of brain capillary in transgenic Tg2576 mouse brain observed 
between ages of 4 and 10 months did not differ to that of normal mice, indicating that soluble 
β-amyloid production does not have any impact on blood-brain supply. However, following 
deposition of cortical β-amyloid plaques from age of 12 months onwards, the density of brain 
capillaries in the somatosensory cortex decreased with further aging in cortical layers II to V 
but being statistically significant in cortical layer IV only (Fig. 3.7). 
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3.2 Developmental and amyloid plaque-related changes in cholinergic 
 neurotransmission in cholinoceptive target regions of transgenic 
 Tg2576 mice 
Based on studies in transgenic Tg2576 mice demonstrating changes in cortical cholinergic 
neurotransmitter function in Tg2576 mice already before any amyloid plaque deposits 
(Klingner et al., 2003), the present study was undertaken to reveal whether age-related 
accumulation of cortical soluble and fibrillar β-amyloid peptides may affect cholinergic nerve 
terminals. The vesicular acetylcholine transporter (VAChT) was used as a marker of 
cholinergic nerve terminals and semiquantitative immunohistochemistry was applied to reveal 
β-amyloid-related changes in cortical cholinergic fibre density.  
The study was designed to include young adult 4-month-old transgenic animals that display 
enhanced levels of cortical soluble human β-amyloid but still no plaque deposition, and aged 
18-month-old transgenic mice with high load of both soluble and plaque-forming fibrillar β-
amyloid peptides. 
 
3.2.1 Visualisation of cholinergic nerve terminals in mouse brain 
Immunohistochemical visualisation of the VAChT in cholinergic nerve terminals was 
compared with immunostaining for choline acetyltransferase (ChAT), the synthesizing 
enzyme of acetylcholine, another marker for cholinergic fibres.  
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Double immunofluorescence using polyclonal rabbit anti-VAChT antibody and the polyclonal 
goat anti-ChAT antibody showed virtually complete overlap of cholinergic fibre staining (Fig. 
3.8). Staining for either VAChT or ChAT revealed similar numbers of immunoreactive fibres 
in the cerebral cortex. However, VAChT staining was much more intense than that for ChAT, 
indicating that immunohistochemistry for VAChT is more useful to detect cholinergic 
terminal fields as that for ChAT. 
 
3.2.2 VAChT-Expression in wild type and transgenic Tg2576 mice 
The VAChT immunostaining was exemplarily assessed in brain sections comprising the 
barrel field of somatosensory cortex 1 (S1BF) from 4-month-old wild type mice. Microscopic 
inspection of VAChT immunohistochemistry revealed the presence of VAChT-expressing 
lattice-like fibre network in the cortical tissue. The VAChT-positive fibres were distributed in 
all directions, but primarily horizontally in the most superficial layers with a vertical 
orientation of the fibres starting in deeper cortical layers. Fine varicose VAChT-
immunopositive fibres pervaded all layers of the somatosensory cortex, as representatively 
shown in Fig. 3.9. 
Semiquantitative evaluation of the density of VAChT-immunoreactivity over all 
somatosensory cortical layers of brains from wild type mice revealed a somewhat higher 
cholinergic fibre density in layers I to III, followed by layers V to VI, while the lowest density 
of VAChT-immunoreactivity was observed in layer IV, regardless of the two ages studied 
(Fig. 3.10).  
Fig. 3.8 A-C: Laser scanning photo micrographs of 
dual immunofluorescent labeling of ChAT (green 
fluorescence, A), and VAChT (red fluorescence, B) 
in the somatosensory cortex (S1BF) of 8-month-old 
wild type mouse.  
C represents the merge of A and B. 
Scale bar: 20 μm. 
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Fig. 3.9: Representative photomicrograph, obtained from laser scanning microscopy of brain section 
immunostained for VAChT, illustrating the cholinergic innervation pattern in layers I, II-III and IV of the 
somatosensory cortex (S1BF) of 4-month-old wild type mouse. Magnification: 40x, scale bar: 100 μm. 
 
In SB1F of wild type mice, the cholinergic fibre density did not change with aging regardless 
of the cortical layer examined (Fig. 3.10C). In contrast, in cortical layers II/III and IV of 
S1BF from transgenic Tg2576 mice, age-related decreases in cholinergic fibre densities were 
observed. VAChT-immunoreactivity in layers II/III and IV of S1BF of 18-month-old Tg2576 
mice was lower by 12%, and 34%, respectively, as compared to corresponding values 
obtained in 4-month-old Tg2576 animals (Fig. 3.10D, and Fig. 3.11B, D). 
When comparing VAChT-immunoreactivity in S1BF of wild type and transgenic Tg2576 
mice, no transgene-related changes in laminar cholinergic fibre densities were observed in 
mice at the age of 4 months (Fig. 3.10A, and Fig. 3.11A, B), while significantly lower 
VAChT densities were found in layers II/III and IV by 11% and 22%, respectively, of S1BF 
from 18-month-old Tg2576 mice as compared to age-matched wild type animals (Fig. 3.10B, 
and Fig. 3.11C, D). 
Preliminary experiments revealed no differences in size and thickness of somatosensory and 
parietal cortex between wild type and transgenic mice (data not shown). 
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Fig. 3.10 A-D: Density of VAChT-immunoreactivity in different layers of S1BF of wild type and transgenic 
Tg2576 mice at ages of 4- and 18-months.  
Data represent the mean ±SD (N=3-5), and are expressed as percentage of VAChT-immunoreactivity per area of 
the respective layer. Statistically significant differences are designated by asterisks.  
* P ≤ 0.05, vs. control as indicated, ANOVA followed by two-tailed Student's t-test. 
A B 
C D 
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Fig. 3.11 A-D: Laser scanning microscopy of VAChT-immunostaining (red fluorescence) in brain sections 
comprising layer II/III of S1BF illustrating the morphological distribution of the cholinergic terminals of 4- (A) and 
18-month-old (C) wild type mice, and of 4- (B) and 18-month-old (D) transgenic Tg2576 mice. Scale bar: 20 μm. 
The results demonstrate age-related selective denervation of cholinergic fibre network in layer II/III. For 
quantitative evaluation, see Fig. 3.10. 
 
To further reveal whether the transgene-related reductions in density of VAChT in layers II to 
IV of S1BF are accompanied by changes in number of cholinergic synapses, the number of 
axonal varicosities and boutons of VAChT-immunoreactive fibres in cortical layers II to IV 
were estimated by using high-power Laser scanning images as representatively shown in Fig. 
3.12. The fine structural analysis showed that cholinergic fibres in tissues of 18-month-old 
transgenic and wild type mice have many swollen varicosities on the terminals, as compared 
to young 4-month-old animals. The elderly animals of both wild type and transgenic mice 
have varicosity, which appear larger in size as compared to those detectable in younger ones. 
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Fig. 3.12 A-D: High-power laser scanning microscopic images of VAChT-Immunostained fibres and boutons in 
layer IV of the somatosensory cortex (S1BF) of 4-month-old wild type (A) and transgenic Tg2576 mice (B), as well 
as 18-month-old wild type (C) and Tg2576 mice (D).  
Note there are similar densities of VAChT-positive axons and boutons in 4-month-old wild type (A) and transgenic 
mice (B), while diminished densities of boutons were observed in 18-month- transgenic mice (D) as compared to 
age-matched wild type animals (C).  
There are also structural abnormalities as increased size of VAChT-positive varicosities in aged mice (C, D) 
compared to 4-month-old mice (A, B). Some terminals in aged tissues are comparable in size to those of elderly 
controls, but others are clearly reduced, or swollen and hypertroph (D). Scale bar 10 µm. 
 
To substantiate these observations a morphometric study of presynaptic boutons in single 
axons in layer II/III and IV of the S1BF was performed by estimating the distances between 
varicosities (boutons) present at particular axons and calculating a mean distance between 
varicosities per each layer (Fig. 3.13). 
In both 4-month-old wild type and transgenic Tg2576 mice the mean distance between 
varicosities of cholinergic fibres in S1BF did not differ regardless of the cortical layer studied 
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(Fig. 3.13). However, the mean distance between varicosities of cholinergic axons increased 
in layers II-III and IV of S1BF of both 18-month-old wild type and Tg2576 mice, as 
compared to corresponding data obtained in 4-month-old wild type mice (Fig. 3.13). 
The loss of varicosities assessed in S1BF of 18-month-old mice was slightly less in transgenic 
Tg2576 mice than in age-matched wild-type animals, detectable both in layers II-III (age-
related increase in mean distance between varicosities of 108.1 ±3.8% in Tg2576-mice vs. 
113.2±2.9% in wild type animals), and in layer IV (112.8±3.9% vs. 120.57±5.39%, 
respectively; Fig. 3.13). 
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Figs. 3.13: Mean distance between varicosities present on VAChT-immunostained fibres determined in layers II-
III, and IV of S1BF from wild type and transgenic Tg2576 mice at ages of both 4 and 18 months.  
Data are expressed as percentage of the mean distance detected in S1BF of 4-month-old wild type mice 
(=100%), and represent the mean ±SD (N=3-5). Statistically significant differences are designated by asterisks.  
* P≤0.05, ** P≤0.01, vs. control as indicated, ANOVA followed by two-tailed Student's t-test. 
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3.3 Role of cholinergic system in β-amyloid-related changes in the 
 cerebrovascular system of transgenic Tg2576 mice 
There is strong evidence that central cholinergic pathways are involved in the regulation of 
cerebral cortical blood flow. Using an immunohistochemical approach, the question should be 
addressed whether the basal forebrain cholinergic innervation of cortical microvessels may be 
affected by accumulation of β-amyloid deposits. To reveal any relationship of cerebral blood 
vessels, cholinergic innervation, and β-amyloid plaque deposition, the parietal cortex of 18-
month-old transgenic Tg2576 mice was examplarily selected. 
In preliminary experiments, the usefulness of Solanum tuberosum lectin (Potato lectin) as a 
marker to label both vessels, β-amyloid plaques, and activated microglial cells, was tested 
(chapter 3.3.1). 
 
3.3.1 Solanum tunerosum lectin (STL) histochemistry in visualisation  
 of brain vessels, β-amyloid, and microglia 
3.3.1.1 Solanum tunerosum lectin and brain vessels 
To reveal whether STL histochemistry labels brain capillaries, which can also be detected by 
immunohistochemistry for GLUT1, brain sections comprising the parietal cortex of 18-
month-old Tg2576 mice were subjected to histochemistry for STL followed by 
immunostaining for GLUT1. Visualization of lectin and immunoreactivity by Laser scanning 
microscopy demonstrates a co-localization of STL and GLUT1-immunoreactivity of cerebral 
blood brain vessels (Fig. 3.14), indicating the usefulness of STL to label cerebral capillaries. 
 
 
Fig. 3.14 A-C: Laser scanning photomicrograph of double staining with Solanum tuberosum lectin (STL, Potato 
Lectin) histochemistry (green fluorescence, A), and GLUT1 immunohistochemistry (red fluorescence, B) in 
parietal cortex of 18-month-old transgenic Tg2576 mouse, demonstrating overlapping signals of STL binding and 
GLUT1-immunoreactivity (merge, C). Magnification: 40x, zoom mode 0.7; scale bar: 50 μm. 
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3.3.1.2 Solanum tuberosum lectin and β-amyloid plaques 
To answer the question which kind of β-amyloid (diffuse or fibrillar plaques), is stained by 
Solanum tuberosum lectin (STL), brain sections were stained with STL and immunostained 
with 4G8, a monoclonal anti-human amyloid beta protein, and counterstained with 
Thioflavine S, which labels fibrillar plaques. No labeling was observed in non-transgenic, 
age-matched littermates (data not shown). 
Sections immunolabeled for β-amyloid (4G8) and counterstained with Thioflavin S, 
demonstrated the presence of both diffuse (Thioflavine-S-negative) and fibrillar (Thioflavin-
S-positive) β-amyloid deposits in the parietal cortex of 18-month-old Tg2576 mice (Fig. 
3.15). In brain sections that did not receive a pretreatment with formic acid, the antibody 4G8 
stained the amyloid core, and weakly the halo of the senile plaques (Fig. 3.15C).  
 
 
Fig. 3.15 A-F: Laser scanning photomicrographs of brain sections comprising the parietal cortex of 18-month-old 
transgenic mouse Tg2576, stained with Solanum tuberosum lectin, STL (red fluorescence, A), Thioflavin S (green 
fluorescence, B), and immunostained with 4G8 (blue fluorescence, C). 
Images D to F represent merged presentations of two markers:  
D: Dual staining with STL and Thioflavine S. E: Dual staining with 4G8 and Thioflavin S. F: Triple staining with 
STL, Thioflavin S and 4G8. Scale bar: 50 μm. 
 
Labeling of β-amyloid by 4G8 and Thioflavin S in one and the same brain section allows to 
differentiate between fibrillar, Thioflavine-S positive β-amyloid, and the total amount of β-
amyloid immunostained by 4G8. The presence of amyloid fibrils within a plaque was 
independent of its size. While some small plaques clearly contained amyloid fibrils, numerous 
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large 4G8-positive plaques were found to be Thioflavin-S-negative (data not shown). The 
comparison of plaque staining pattern by STL and 4G8 revealed a strong correlation 
suggesting that STL labels both diffuse and fibrillar β-amyloid in brain sections that were not 
pretreated with formic acid (Fig. 3.15 A,C,F). 
 
 
Fig. 3.16 A-F: Laser scanning photomicrographs of formic acid pretreated brain sections comprising the parietal 
cortex of 18-month-old transgenic mouse Tg2576, labeled with Solanum tuberosum lectin, STL (red fluorescence, 
A), immunostained for β-amyloid (4G8, green fluorescence, B), and for astroglial cells (GFAP, blue fluorescence, 
C).  
Formic acid preteatment of brain sections markedly enhanced the intensity of 4G8 immunoreactivity to label β-
amyloid deposits as compared to β-amyloid staing by STL (D, merge of A and B). Numerous reactive astrocytes 
(C), (E, represents merge of A and C) have been detected closely associated with diffuse and fibrillar β-amyloid 
deposits. F, represents a triple staining pattern, merge of A, B and C. Scale bar: 50 μm. 
 
In brain sections that received a pretreatment with formic acid before starting 
immunohistochemistry, the intensity of 4G8 immunostaining of senile plaques was 
significantly increased, which allowed to visualize even small primitive diffuse plaques (Fig. 
3.16). The formic acid pretreatment of brain sections appeared to apparently increase density, 
and mean size of β-amyloid deposits (Fig. 3.16) as compared to analysis of sections not 
pretreated by formic acid (Fig. 3.15). 
 
3.3.1.3 Solanum tuberosum lectin staining to visualize glial cells 
In order to reveal which kind of glia (micro-or astroglial cells) is stained by STL, brain 
sections were subjected to either immunostaining with anti-CD11b antibody, that labels 
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microglial cells, or glial fibrillary acidic protein (GFAP, that labels astroglial cells), and in 
each case counterstained with STL. 
 
 
Fig. 3.17 A-C: Laser scanning photomicrographs of brain sections comprising the parietal cortex of 18-month-old 
transgenic mouse Tg2575, labeled with Solanum tuberosum lectin, STL (green fluorescence, A), and 
immunostained for microglial cells (anti-CD11b antibody, red fluorescence, B). Note the co-localization of STL 
signals in A, (labels both plaques and microglial cells surrounding the plaques), and CD11b immunoreactivity in B 
(labeled microglial cells), as presented in C (merge of A and B). Scale bar: 20 μm.  
 
 
 
Fig. 3.18 A-C: Laser scanning photomicrographs of brain sections comprising the parietal cortex of 18-month-old 
transgenic mouse Tg2576, labeled with Solanum tuberosum lectin (STL, red fluorescence, A), and 
immunostained for astroglial cells (anti-GFAP antibody, blue fluorescence, B).  
Note the presence of reactive astrocytes (B) in close proximity of STL-positive β-amyloid deposits (A), which are 
not co-localised with lectin staining (C, merge of A and B). Scale bar: 50 μm. 
 
In brain sections comprising the parietal cortex of 18-month-old transgenic Tg2576 mice, 
both diffuse and fibrillary β-amyloid deposits induced prominent glial responses in close 
proximity to the sites of plaques (Fig. 3.16 C, E, F; Fig 3.17 A-C; and Fig. 3.18 B, C). 
Activated microglia as visualized by CD11b-immunohistochemistry (Fig. 3.17B), appeared in 
clusters that are localized upon or very close to β-amyloid plaques. Interestingly, not all 
clusters of CD11b-positive cells are associated with an amyloid core, indicating that both 
diffuse and compact plaques were surrounded by activated microglia. This finding was further 
validated by double immunofluorescent staining for both β-amyloid (STL) and CD11b (Fig. 
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3.17 A, B), using confocal laser scanning microscopy, showing a virtually complete overlap 
of STL staining with immunoreactivity for microglial cells (Fig. 3.17C). The data indicate the 
usefullness of STL to detect microglial cells in brain sections of Tg2576 mice. 
Immunolabeling of brain sections for astroglial cells (anti-GFAP antibody; Fig. 3.18B) and 
counterstained with STL (Fig. 3.18A) demonstrated that presence of reactive astrocytes 
clustered around the plaques, but were not observed upon the cores. There are also clusters of 
activated astrocytes that were not associated with amyloid plaque cores, being presumably 
around diffuse plaques (Fig. 3.18B, C). STL fluorescence was not co-localized with 
immunoreactivity for astroglial cells suggesting that STL does not label astroglial cells (Fig. 
3.18C). 
 
3.3.2 Cholinergic perivascular innervation of cerebral cortical microvessels in 
 transgenic Tg2576 and wild type mice 
To reveal any differences in perivascular cholinergic innervation of cerebral cortical 
microvessels in transgenic Tg2576 and wild type mice during aging, a semiquantitative 
immunohistochemical study was performed, using the S1BF region as a representative brain 
region. Cortical perivascular cholinergic nerve fibres were demonstrated by immuno-
histochemistry, using a polyclonal anti-VAChT antibody. Determination of brain blood 
vessels was performed with Solanum tuberosum lectin (STL) staining. Neuronal marker 
NeuN was used as a neuronal marker for recognition of cortical layers in the triple staining of 
mouse brain slices. 
As representatively shown in Fig. 3.19, a rich network of VAChT-immunoreactive 
cholinergic fibres has been observed in the S1BF from 8-month-old mice. In all cortical layers 
studied cholinergic neurovascular associations surrounding intraparenchymal blood vessels of 
varying sizes (capillaries, arterioles and larger vessels) were observed (Fig.3.19). 
High power Laser scanning microsopy demonstrated that some cholinergic fibres did not have 
close contacts with the blood vessels but ended within a distance of 3 µm of the vessels, while 
other terminals were found attached on or in the immediate vicinity of the vessels wall (Fig. 
3.20).  
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Fig. 3.19: Representative example of a double fluorescent Laser scanning micrograph demonstrating the 
cholinergic perivascular innervation (red fluorescence) of capillaries and large penetrating arteries (green 
fluorescence) in the S1BF area of a 8-month-old transgenic Tg2576 mouse. VAChT-positive terminals (red) are 
visible directly opposed to the vascular basement membrane, or located within the immediate vicinity of cortical 
vessels (green). Scale bar represents 50 μm.  
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A      
 
B      
Fig. 3.20: Representative series of 2D high power Laser scanning photomicrographs along the z-axis (A1-3, B1-
3) of double immunoflourescent labeling of brain sections from 8-month-old Tg2576 mouse comprising the S1BF 
region, illustrating by virtual three-dimensional-imaging in more detail the distribution of perivascular cholinergic 
terminals (red fluorescence) around blood vessels (green fluorescence).  
VAChT-positive nerve fibres (red) are closely associated and partly attached on the wall of the large vessel 
(green; A, see white arrows). The cholinergic nerve fibres appear to overlay the vessel wall, or being apposed 
directly to the wall (B, indicated by white arrows) and located within the immediate vicinity of small microvessels. 
Scale bar: 10 μm. 
 
To reveal any transgene-mediated changes in the cholinergic innervation of cerebral cortical 
blood vessels, the number of cholinergic terminal endings / vessel contacts within a 3-µm-
distance range from the vessel was estimated and correlated with the total length of blood 
vessels present in a particular cortical layer of the S1BF region. The ratio of perivascular 
cholinergic terminal endings / vessel contacts and total length of blood vessels indicates the 
perivascular density of cholinergic innervation of blood vessels in a particular region/layer. 
At ages of 6 and 8 months the cholinergic innervation of blood vessels in the S1BF region did 
not significantly differ between transgenic and wild type mice regardless of the cortical layer 
examined (Fig. 3.21).  
However, during further postnatal development of transgenic Tg2576 mice up to the age of 18 
months a significant loss of density of cholinergic innervation of blood vessels was observed 
in all S1BF cortical layers except layer VI as compared to the corresponding innervation level 
at the age of 6 months (Fig. 3.21). In layer I of the S1BF from 18-month-old Tg2576 mice the 
reduction in vascular cholinergic innervation amounted to about 30%, in layer II-III by 30%, 
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Fig. 3.21: Developmental pattern of perivascular 
cholinergic innervation estimated in cortical layers 
I, II-III, IV, V and VI of the S1BF region of 
transgenic Tg2576 mice (black column) and non-
transgenic littermates (grey column) at ages 
ranging between 6 and 18 months.  
The data are expressed as ratio of cholinergic 
terminal endings/vessel contacts (located within a 
3-µm-distance range from the vessels) and the 
total length of microvessels assessed in a 
particular cortical layer of S1BF region and 
represent the mean ± S.D. (N=3-5).  
* P ≤0.05 **P ≤ 0.01, ***P ≤ 0.001, ANOVA 
followed by two-tailed Student's t-test. 
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in layer IV by 26%, and in layer V by 22% as compared to the corresponding levels estimated 
in 6-month-old Tg2576 animals (Fig. 3.21). In contrast, in wild type mice, decreases in 
perivascular cholinergic innervation during aging were only observed in layer I (by 27%), and 
layer V (by 16%) of the S1BF from 18-month-old mice as compared to the corresponding 
values calculated in 6-month-old wild type mice  (Figs. 3.21).  
However, in 18-month-old Tg2576 mice a significant reduction in perivascular cholinergic 
innervation was only observed in cortical layers II-III by about 16% and IV by about 24% 
compared to that estimated in layers II-IV of S1BF from 18-month-old wild type mice (Fig. 
3.21). 
In order to disclose whether the changes in perivascular cholinergic innervation observed in 
the S1BF region from 18-month-old Tg2576 mice are due to the presence of β-amyloid 
plaques, the perivascular cholinergic innervation densities were estimated both in areas within 
the S1BF with no plaque depositions, and in neighboured areas that demonstrated a 
significant plaque load. As graphed in (Fig.3.22), in the S1BF region from 18-month-old 
transgenic Tg2576 mice there was no significant difference in the perivascular cholinergic 
innervation in areas that demonstrated significant plaque load and those with no plaque 
deposits, regardless of the cortical layer examined (Fig.3.22). 
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Fig. 3.22: Comparison of the 
perivascular density of 
cholinergic innervation 
estimated in areas of cortical 
layers II-III, IV, V and VI of 
S1BF region from 18-month-old 
transgenic Tg2576  mice that 
demonstrated a significant 
plaque load (black columns) and 
in areas with no β-amyloid 
plaque deposits (grey columns). 
The data are expressed as ratio 
of cholinergic terminal endings / 
vessel contacts (located within a 
3-µm-distance range from the 
vessels) and the total length of 
microvessels assessed in a 
particular area of S1BF region 
and represent the mean ± SD 
(N=3-5).  
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CHAPTER 4: DISCUSSION 
4.1 β-amyloid and brain vascular system:  
 the vascular hypothesis of Alzheimer's disease 
 
4.1.1 Evidences of a role of vascular mechanisms in Alzheimer's disease 
In the brain, the cerebral blood flow is tightly regulated to assure adequate and timely blood 
supply to brain regions that have momentarily high energy demand because of enhanced 
neural activity, a phenomenon called functional hyperemia (Iadecola et al., 2009). Already at 
very early stages of AD, changes in the cerebral blood flow, such as reduced blood supply at 
rest and altered perfusion to activated areas have been observed, which provided evidence for 
suggesting a causal relationship between vascular mechanisms and the development of 
sporadic AD. This vascular hypothesis of AD was firstly formulated by de la Torre and 
Mussivand in 1993 (for reviews, see de la Torre, 2010; Kalaria, 2010; Nicolakakis and 
Hamel, 2011). Insufficient cerebral blood flow may induce hypoxia-sensitive pathways 
leading to inflammation with upregulation of pro-inflammatory cytokines, and to oxidative 
stress with generation of reactive oxygen species which may be detrimental to vascular 
integrity and function. Indeed, cerebrovascular abnormalities such as thickening of the 
microvascular basement membranes, decreased luminal diameter, and microvascular 
degeneration, in particular in the temporal-parietal cortex, have frequently been observed in 
AD patients (Nicolakakis and Hamel, 2011).  
 
In advanced AD cases β-amyloid (Aβ) deposition occurs also in cerebral vessels (cerebral 
amyloid angiopathy, CAA) that may result in smooth muscle cell degeneration and 
weakening of the vascular wall, impairing vasomotor function, and increasing the risk of 
cerebral hemorrhage (Weller et al., 2009). Indeed, the recently detected brain microbleeds 
(small dot-like lesions) in AD brains have been suggested to be the missing link between the 
amyloid cascade hypothesis and the vascular hypothesis (Cordonnier and van der Flier, 2011). 
The CAA which is observed during normal aging, and in the majority of AD cases, is likely 
caused by the failure of Aβ elimination from the brain parenchyme, whereas receptor for 
advanced glycation end products (RAGE), and low density lipoprotein receptor related 
protein 1 (LRP1) have been suggested to play a role in controlling the Aβ transport through 
the blood brain barrier (for reviews, see Zlokovic, 2008b, 2011). Pathology of the blood brain 
barrier (BBB) is an early finding in white matter lesions associated with AD and altered 
function of BBB transport may also have an impact on the accumulation of Aβ in the brain 
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(Kalaria, 1992; Zlokovic, 2008; Farrall and Wardlaw, 2009). Moreover, serum inflammatory 
proteins may increase BBB permeability, what exacerbate the loss of BBB integrity in an 
escalating cycle of Aβ protein accumulation and BBB damage (Farrall and Wardlaw, 2009). 
Recently, Zlokovic (2011) presented a two-hit vascular hypothesis of Alzheimer’s disease.  
Hit one represents the primary damage of brain microcirculation resulting in neuronal 
dysfunction and injury mediated by BBB dysfunction associated with leakage and secretion of 
many neurotoxic molecules and impaired brain capillary flow, while dysfunctional BBB also 
leads to impaired β-amyloid clearance, and oligaemia to increased β-amyloid generation and 
accumulation in the brain (hit two).    
A recent study in transgenic AD-like mice (Tg2576) further supported the “clearance 
hypothesis” demonstrating impaired perivascular solute drainage from the brain in aged mice 
as compared to younger ones (Hawkes et al., 2011). Currently, in a transgenic AD mouse 
model with strong CAA pathology, a particular role of early perivascular astrocytic 
dysfunction in impairing cerebrovascular and metabolic pathology has been suggested 
(Merlini et al., 2011).  
 
Studies in transgenic mouse models of AD suggested that the compromised cerebral 
hemodynamics observed in AD appears to be associated with inflammation (Paris et al., 
2003). The local activation of microglia and reactive astrocytes is accompanied by production 
and secretion of proinflammatory cytokines such as interleukin-1β (IL-1β), tumour necrosis 
factor (TNF)-α., and transforming growth factor (TGF)-β1. Endothelial cells are known to 
respond sensitive to inflammatory stimuli by production of reactive oxygen species that may 
further exacerbate the vascular damages (Iadecola, 2004). 
 
A number of risk factors are assumed to mediate the cerebrovascular dysfunctions and to 
trigger AD pathology, such as hypertension, hyperlipidemia, enhanced homocysteine levels, 
diabetes type 2, metabolic syndrome (obesity, hypertension, cardiovascular disease, 
atherosclerosis) as well as genetic factors (ε4 allele of ApoE), age, and life style (Rocchi et 
al., 2009; de la Torre, 2010; Milionis et al., 2008). However, it is still a matter of debate 
whether neurovascular dysfunction and vascular lesions play a causative role for the 
neurodegenerative processes as suggested by a number of reports (for review, see Zlokovich, 
2008b). However, regardless of that, cerebrovascular diseases appear to play an important role 
in determining the presence and severity of the clinical symptoms of AD (Snowdon et al., 
1997). 
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4.1.2 Effect of β-amyloid on brain vascular system 
The microvascular degenerations observed in AD may also be the consequence of the 
vasoactive detrimental effects of Aβ. A number of studies provided evidence that the 
cerebrovascular degenerations are related to Aβ deposition in AD (Attems et al., 2004; Buee 
et al., 1994, 1997; Fischer et al., 1990; Kalaria et al., 1998; Kalaria, 2002; Mann et al., 1986; 
Suter et al., 2002). Amyloid deposition occuring in cerebral vessels, results in smooth muscle 
cell degeneration and leads to weakening of the vascular wall and increasing the chance of 
lobar hemorrhages (Itoh et al., 1993; Weller et al., 2009).  
Observations in transgenic AD-like mice also revealed Aβ-mediated impairments of 
endothelium-dependent regulation of cortical microcirculation, abnormal vascular 
autoregulation, reduced cerebral blood flow and attenuated cerebrovascular reactivity to 
functional hyperemia already before onset of any plaque load, further supporting the link of 
Aβ to the mechanisms of vascular dysfunction (for comprehensive reviews, see Iadecola et 
al., 2009; Nicolakakis and Hamel, 2011). However, the view that elevated soluble Aβ levels 
are sufficient to cause cerebrovascular dysfunction has also been challenged by studies in 
Tg2576 transgenic mouse model (Shin et al., 2007). 
 
Aβ may cause degeneration of both the larger perforating arterial vessels as well as cerebral 
capillaries, presumably mediated through the induction of reactive oxygen species by 
activation of NADPH oxidase, which may subsequently severely affect regulation of cerebral 
blood vessels and brain perfusion as well as impair the blood brain barrier (for reviews, see 
Cole and Vassar, 2009; Iadecola et al., 2009; Smith and Greenberg, 2009; Weller et al., 2009).  
The enzyme NADPH oxidase has emerged as a major source of vascular oxidative stress and 
experimental studies demonstrated that NADPH oxidase-derived free radicals may play a role 
in the cerebrovascular abnormalities associated with Aβ (Iadecola, 2004; Park et al., 2008; 
Iadecola et al., 2009). Free radicals can trigger inflammation by activating redox sensitive 
transcription factors, like NFkB and AP1 (Iadecola, 2010). Activation of NMDA receptors by 
excess glutamate is also known to promote a breakdown of the blood brain barrier and 
resulting in dysfunction of the affected endothelial barrier integrity (Sharp et al., 2003; Del 
Zoppo and Mabuchi, 2003; see for review Humpel, 2011). Endothelial dysfunction caused by 
oxidative stress can initiate release of vascular endothelial growth factor (VEGF) and 
prostanoids, with promotion of vascular leakage, protein extravasation, and inflammation 
(Marchesi et al., 2008). Further, extravasated plasma protein triggers perivascular edema and 
axonal demyelination (Farrall and Wardlaw, 2009). Demyelination, in turn, increases the 
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oxygen use of axons and enhances the local energy deficit and hypoxia (Trapp and Stys, 
2009; Fotuhi et al., 2009; Ihara et al., 2010: Iadecola 2010).  
 
Aβ is also a potent vasoconstrictor in the brain, as has been shown in vivo and in vitro by 
application of exogenous Aβ to normal blood vessels and to mouse cortex. Moreover, Aβ 
peptides have been described to inhibit angiogenesis both in vitro and in vivo (Paris et al., 
2004a; Paris et al., 2004b), and deregulation of angiogenic factors may contribute to various 
neurological disorders including neurodegeneration (for review, see Ruiz de Almodovar et al., 
2009). One of the key angiogenic factor, the vascular endothelial growth factor (VEGF), a 
highly conserved heparin-binding protein (Sun and Guo, 2005), was originally found in 
vascular endothelial cells and is able to induce vascular endothelial cell proliferation, 
migration and vasopermeability in many types of tissue (Ferrara et al., 2003).  
Increased intrathecal levels of VEGF have also been observed in brains of AD patients as 
compared to age-matched healthy individuals (Kalaria et al., 1998; Tarkowski et al., 2002; 
Yang et al., 2004) that has been correlated with the clinical severity of the disease (Ryu et al., 
2009). However, the functional significance of VEGF up-regulation in the pathogenesis and 
progression of AD is still a matter of debate. While VEGF and other angiogenic factors were 
found to be enhanced in AD (Pogue and Lukiw, 2004; Thirumangalakudi et al., 2006; 
Vagnucci and Li, 2003; Desai et al., 2009), neovascularization has been observed only in the 
hippocampus of AD patients (Desai et al., 2009). 
The brain VEGF is sequestered by amyloid plaques consequently reducing its bioactivity 
(Yang et al., 2004). Vice versa, Aβ may inhibit vasculogenesis through impairment of VEGF 
signalling (Patel et al., 2010), and the vascular regeneration is suppressed through induction 
of endothelial autophagy (Hayashi et al., 2009). Therefore, in AD a loss of neurovascular 
trophic support by inducing a state of ″neurotrophin resistance″ via impairment of growth 
factor signaling through pro-inflammatory cytokines has been suggested (Iadecola 2010; 
Tong et al., 2008; Venters et al., 2000). Moreover, the transcriptional profiling of the 
homeobox gene MEOX2, a regulator of vascular differentiation, considerably altered in AD 
and may mediate reductions in brain capillary density and resting cerebral blood flow, loss of 
the angiogenic response to hypoxia as revealed by studies with knock-out mice (Wu et al., 
2005). 
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4.1.3 Effect of ischemia and hypoperfusion on APP processing 
There are reports that ischemia and hypoperfusion may trigger accumulation and cleavage of 
APP into Aβ, and its deposition in the brain, as well as hyperphosphorylation of tau and PHF 
formation (for reviews, see Zlokovic, 2008, 2011). The upregulation of VEGF in response to 
hypoxic, ischemic or hypoglycemic stress (Marti and Risau, 1998; Marti et al., 2000; Stein et 
al., 1995; Yancopolous et al. 2000) suggests its involvement also in processing of APP. In 
turn, APP is also highly expressed in the endothelium of neoforming vessels (Paris et al., 
2005), and inhibitors of β-and γ-secretases have been reported to inhibit angiogenesis and 
tumour growth (Paris et al., 2005), suggesting a role of APP metabolism also during 
angiogenesis. Recently, VEGF has been shown to also be involved in the induction of 
microglial-mediated inflammation by Aβ deposits via the microglial VEGF receptor subtype 
Flt-1 serving as a chemotactic receptor to mobilize microglial cells (Ryu et al., 2009).  
As vascular endothelial cells are also capable to express and to secrete APP (Ciallella et al., 
1999), it has been hypothesized that VEGF may also be involved in formation and deposition 
of Aβ. This hypothesis has been addressed by examining the effect of VEGF on APP 
processing in brain slice cultures, as well as in primary neuronal, astroglial and vascular 
endothelial cells derived from AD-like transgenic Tg2576 mice (Bürger et al., 2009, 2010). 
Exposure of brain slices by VEGF resulted in an inhibition of the formation of soluble Aβ 
peptides, which was accompanied by a transient decrease in β-secretase activity, as compared 
to controls (Bürger et al., 2009). Similar studies in primary neurons, astrocytes, and 
endothelial cells expressing the Swedish mutation of human APP, further provided evidence 
that VEGF affects APP processing but differentially acting in cells that form the neuron-glia-
vascular unit (Bürger et al., 2010, Schliebs et al., 2011). 
 
4.1.4 Effect of β-amyloid on cholinergic function in brain vascular system 
There is a large body of evidence that cerebral blood flow and local glucose delivery is 
controlled by neuronal activity, known as neurometabolic and neurovascular coupling 
(Iadecola, 2004; Girouard and Iadecola, 2006; Hamel, 2006; Nicolakakis and Hamel, 2011). 
Dysfunctions of the regulation of the cerebral blood circulation may affect vital control 
mechanisms that ensure delivery of adequate amounts of substrate and to maintain the 
homeostasis of the microenvironment of the neurovascular unit. The neurovascular unit 
defines the cellular interaction between brain capillary endothelial cells, pericytes, the end 
feet of perivascular astrocytes, and neuronal axons (Iadecola, 2004; Zlokovic, 2011). Pial 
arteries at the surface of the brain are densely innervated by perivascular nerves that originate 
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from autonomic and sensory ganglia, whereas intracerebral arterioles and capillaries receive 
afferents that originate from subcortical neuronal centers as well as from local cortical 
interneurons. (for comprehensive review, see Hamel, 2006; Van Beek and Claassen, 2011).  
 
Basing on findings by immunocytochemistry and electron microscopy, the cholinergic axons 
originating from the basal forebrain project not only to the cortical neuropile but also to 
arterioles, capillaries and to perivascular astrocytes within the cerebral cortex (Vaucher and 
Hamel, 1995). Furthermore, there is physiological evidence that the central cholinergic 
pathways are involved in the regulation of cerebral cortical blood flow. Electrical or chemical 
stimulation of cholinergic basal forebrain neurons resulted in increased cerebral blood flow 
(Biesold et al., 1989; Lacombe et al., 1989; Kurosawa M. et al., 1989; Hamel, 2004). The 
involvement of ACh as a neurotransmitter in the control of regional cerebral blood flow was 
further demonstrated by administration of cholinergic drugs (Elhusseiny and Hamel, 2000; 
Farkas and Luiten, 2001). While application mAChR antagonist decreased cerebral blood 
flow, the inhibition of AChE led to increased cerebral blood flow (Farkas and Luiten, 2001). 
This response was found to be dependent on nitric oxide (NO) production, and presumably 
mediated through the M5-mAChR sybtype (Elhusseiny and Hamel, 2000). The basal 
forebrain cholinergic fibers can either directly affect the cerebrocortical microvasculature, or 
innervate subpopulations of GABAergic interneurons releasing the vasodilators NO and VIP 
(Vaucher et al., 1997; Cauli et al., 2004). The interneurons appear to serve as a functional 
relay to adapt perfusion to locally increased neuronal activity (Hamel, 2006). 
 
On the other hand, damages of the neurovascular unit either by oxidative stress, inflammation, 
or Aβ accumulation may induce degeneration of vascular cholinergic nerve terminals and 
subsequent retrograde cell death of basal forebrain cholinergic neurons. The loss of 
cholinergic innervation of components of  the neurovascular unit may affect APP processing 
with enhanced Aβ formation and deposition, microglia activation and inflammation, thus 
suggesting a link between Aβ production, impairments in cerebrovascular function and basal 
forebrain cholinergic deficits in AD (cholinergic-vascular hypothesis of AD; Humpel and 
Marksteiner, 2005; Claasen and Jansen, 2006). Indeed, a semiquantitative 
immunohistochemical study in aged Tg2576 mice revealed an Aβ-mediated decrease in 
cholinergic innervation of cortical blood vessels (Kouznetsova and Schliebs, 2006), which has 
been assumed to contribute to the alterations of the cerebrovascular system observed in 
transgenic Tg2576 mice (Bürger et al., 2009).  
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4.2 Aim of study and main results obtained 
The present study was undertaken to elucidate whether the age-related Aβ production and 
deposition may affect the morphological integrity of cerebral microvessels, cholinergic 
terminals and their intracerebral neurovascular architectonic, and whether size or type of 
plaques play a role in this process. We wanted to contribute to the question whether changes 
in cerebral vessels, cortical cholinergic denervation, Aβ formation and deposition may 
interact with each other.  
The availability of transgenic mice that produce human Aβ peptides from birth and 
progressively develop Alzheimer-like -amyloid deposits in the aged brain appears to be a 
unique experimental approach to address such questions. To in vivo characterize the 
developmental relationship of amyloid formation and deposition, cortical cholinergic 
innervation and cerebrovascular abnormalities, transgenic Tg2576 mice that overexpress the 
Swedish double mutation of human APP, and demonstrate significant cerebral cortical 
deposition of Aβ plaques at ages from 9 months onwards (Apelt et al., 2004), were considered 
as an appropriate in vivo animal model. In this developmental study transgenic Tg2576 mice 
at ages between 4 and 18 months were investigated in order to reveal any effect of both 
soluble Aβ and Aβ plaque deposits on maturation and morphological integrity of cerebral 
cortical capillaries, cholinergic terminals and their cerebral neurovascular relationship with 
each other.  
Using the somatosensory cortex as a representative region, serial cryocut sections, obtained 
from mice at ages ranging from 4 up to 18 months, were subjected to immunohistochemistry 
to label vascular endothelial cells, cholinergic nerve terminals and Aβ plaques, followed by a 
thorough quantitative evaluation of the age-related spatial relationship between cerebral 
cortical capillaries, amyloid plaques and cholinergic terminals, using computer-assisted 
imaging analysis.  
 
The main results obtained are as follows: 
1.  
Density of blood vessels estimated in the somatosensory cortex of transgenic mice did not 
differ to that obtained in wild type mice before onset of plaque deposition (younger than 12 
months). However, in aged, 18-month-old Tg2576 mice, demonstrating high plaque loads, 
decreased blood vessel densities, particularly in layer IV of the somatosensory cortex, were 
observed. 
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2. 
The density of cholinergic terminals estimated in the somatosensory cortex of wild type mice 
did not change with aging regardless of the cortical layer examined, while in cortical layers 
II/III and IV of somatosensory cortex of transgenic Tg2576 mice age-related decreases in 
cholinergic fibre densities were assessed. Quantitative morphometric analysis demonstrated 
an age-related reduction in the number of varicosities on cholinergic fibres, particularly in 
layer IV, in both transgenic Tg2576 mice and non-transgenic littermates. 
 
3. 
Cholinergic innervation of microvessels in the somatosensory cortex decreased with aging in 
both Tg2576 mice (in cortical layers I to V) and non-transgenic littermates (only in layers I 
and V), as revealed by estimating the ratio of the number of cholinergic vascular contacts and 
total length of blood vessel. There was no significant difference in the perivascular 
cholinergic innervation in areas that demonstrated significant plaque load and those with no 
plaque deposits regardless of the cortical layer examined.  
 
4.3 Age-related changes in cerebral cortical microvessels in the presence and 
absence of β-amyloid plaque load 
 
The aim of this part of the study was to elucidate whether the age-related Aβ production and 
deposition may affect the morphological integrity of cerebral microvessels located in the 
vicinity of amyloid plaques, and whether size or type of plaques play a role in this process. 
The developmental profile of blood vessels in the somatosensory cortex of transgenic Tg2576 
mouse brain observed between ages of 4 and 10 months did not differ to that of normal mice, 
indicating that soluble Aβ production does not have any impact on cerebral blood flow. 
However, following deposition of cortical Aβ plaques from age of 12 months onwards, the 
density of brain capillaries in cerebral cortical regions decreased with further aging. Indeed, 
the laser scanning microscopic inspection of brain sections of aged Tg2576 mouse brain 
demonstrated that the distribution of brain vessels in the vicinity of Aβ deposits differed 
between senile and diffuse plaques. The lower density of capillaries in areas very close to 
senile plaques as compared to that located more distal, indicates an impaired blood supply of 
cortical tissue in close vicinity to senile plaques. Moreover, the density of microvessels 
estimated in cortical regions with high plaque load was found to be significant lower as 
compared to areas with low plaque burden, which is in agreement with a previous study (Paris 
et al., 2004a). This indicates that the deposition of Aβ plaques nearby to cerebral blood 
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vessels may produce mechanical, displacing actions on the cerebrovasculature. However, 
accumulation of Aβ around vessels may also exert toxic actions on the integrity of cerebral 
capillaries by inducing pro-inflammatory events (Apelt and Schliebs, 2001; Patel et al., 2005), 
including perivascular astrocytosis that may lead to cerebrovascular abnormalities. 
Interestingly, in double transgenic PS1/APPswe Alzheimer mice a decreased cerebral blood 
flow compared to PS1 littermates was observed which could be improved by chronic 
treatment with cyclooxygenase-2 inhibitors, thus suggesting a link between inflammation and 
compromised cerebral hemodynamics in AD (Paris et al., 2003). Indeed, Aβ has been found 
to enhance endothelin-induced vasoconstriction in isolated human cerebral arteries which 
appeared to be mediated through the involvement of a pro-inflammatory pathway (Paris et al., 
2000, 2003). 
 
On the other hand, neuropathological studies demonstrated that Aβ itself is associated with 
structural changes in the vessels including loss of smooth muscle cells, fibrinoid necrosis, and 
weakening of the vessel wall (Greenberg et al., 1995). Similarly, mice overexpressing human 
mutant APP have been observed to develop cerebrovascular amyloid angiopathy, 
morphologically similar to that detectable in the human AD brain (Calhoun et al., 1999; 
Christie et al., 2001; Van Dorpe et al., 2000), and impairments in vessel function of 
vasodilatation by disrupting smooth muscle cell organization (Christie et al., 2001). 
Moreover, in culture Aβ has been shown to be toxic to endothelial cells (Thomas et al., 1996).  
 
Recently it was described that APP is also highly expressed in the endothelium of neoforming 
vessels which led to the suggestion of a role of APP processing during angiogenesis (Paris et 
al., 2005). Both in vitro and in vivo studies in Tg2576 mice demonstrated anti-angiogenic 
actions of Aβ peptides indicating that the amyloidogenic route of APP processing mediated 
through actions of β- and γ-secretases may play an essential role in affecting angiogenesis 
(Paris et al., 2004b, 2005). 
 
Otherwise, there are also reports that ischemia and hypoperfusion may trigger accumulation 
and cleavage of the APP into Aβ, and its deposition in the brain (Bennett SA. et al., 2000; 
Jendroska et al., 1995). The upregulation of the vascular endothelial growth factor (VEGF) in 
response to hypoxic, ischemic or hypoglycemic stress (Marti et al., 1998, 2000; Stein et al., 
1995; Yancopolous et al. 2000) suggests its involvement also in APP processing. 
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In a recent study, this hypothesis has been addressed by examining the effect of VEGF on 
APP processing in brain slice cultures and primary neuronal cells derived from brain tissue of 
Tg2576 mice (Bürger et al., 2009, 2010). Already six hours of exposure of brain slice cultures 
by VEGF resulted in an inhibition of the formation of soluble Aβ peptides, which was 
accompanied by a transient decrease in β-secretase activity, providing evidence of a role of 
VEGF in β-amyloidogenesis (Bürger et al., 2009). 
 
In conclusion, the data presented in this part of the study add further evidence that Aβ, in 
addition to its well-described neurotoxic effects, may also contribute to neuronal dysfunction 
through its actions on the cerebrovasculature.  
 
4.4 Age-related changes of cholinergic terminals in cholinoceptive target 
regions in the presence and absence of β-amyloid plaque load 
 
Based on investigations demonstrating that already soluble Aβ, before any amyloid plaque 
formation, may induce changes in a number of cholinergic function (Klingner et al., 2003), 
the study was designed as semiquantitative immunohistochemistry to determine distribution 
and density of VAChT as specific cholinergic marker in brain sections from both young adult 
4-month-old transgenic Tg2576 mice that display enhanced levels of cortical human Aβ 
peptides but not yet any plaque deposition, and from aged 18-month-old transgenic animals 
with high load of both soluble and plaque-forming fibrillary Aβ peptides.  
 
4.4.1 VAChT – a reliable marker for detection of cholinergic terminals in 
cerebral cortex 
 
The VAChT is a 12-transmembrane domain protein with N- and C-terminal regions directed 
to the cytosol. VAChT is predominantly present in synaptic vesicles in cholinergic nerve 
endings (Gilmor et al., 1996; Weihe et al., 1996; Mundigl et al., 1993; Nakata et al., 1998). 
Endogenous VAChT-immunoreactivity observed in varicosities is co-localized with synaptic 
vesicle marker such as synaptophysin, synaptotagmin I and FM4-64 (Barbosa et al., 1999; 
Santos et al., 2000; for review, see Prado, 2002). 
Therefore, VAChT has been used as a specific marker for immunohistochemical visualisation 
of cholinergic neuronal fibres and nerve terminals (Weihe et al. 1996). The rabbit polyclonal 
anti-VAChT serum (Phoenix Pharmaceuticals, Inc., Belmont, USA) used in this study, was raised 
against a synthetic peptide representing the C-terminus from cloned rat VAChT, which was 
used to identify the presence of VAChT in the mouse cerebral cortex. 
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In preliminary studies, the immunohistochemical detection of VAChT in cholinergic nerve 
terminals in mouse brain was compared to that for ChAT, the mostly used marker for 
detection of cholinergic cell bodies and partly terminals. In the present study double 
immunofluorescence using polyclonal rabbit anti-VAChT serum and the polyclonal goat anti-
ChAT antibody demonstrated a complete overlap of immunoreactive cholinergic fibres in the 
parietal cortex (see 3.2.1). Microscopic inspection of VAChT immunohistochemistry revealed 
the presence of lattice-like fibre network with fine varicose pervading all VAChT-
immunopositive fibres in cortical tissue. However, VAChT staining was much more intense 
than that for ChAT, allowing a higher quality of staining and more reliable images to be used 
for semiquantitative evaluation. Moreover, in situ hybridization histochemistry demonstrated 
similar distributions of VAChT mRNA and ChAT mRNA as compared to that of the 
corresponding proteins (Ichikawa et al., 1997), and VAChT binding studies also correlated 
with ChAT activities (Kish et al., 1990; Efange et al., 1997), thus providing strong evidence 
that VAChT immuhistochemistry represents a useful and reliable marker to detect cholinergic 
terminals in mouse cerebral cortex. 
 
4.4.2 The barrel field of the somatosensory cortex 1 (S1BF) as a model region 
to reveal age-related changes in cholinergic innervation 
 
The mouse S1BF was chosen as a representative model region to investigate age-related and 
cortical layer-specific changes in the density of cholinergic terminals both in the presence and 
absence of amyloid plaque load. 
The mean density of VAChT-immunoreactivity determined in S1BF of wild type and of 
transgenic Tg2576 mice but assessed in areas distal from any plaque (> 100 µM), was 
comparable regardless of the cortical layer studied. The immunohistochemistry demonstrated 
a normal anatomical distribution and morphology of cholinergic intracortical network in 
S1BF, while the fibre density was highest in cortical layers I-III, followed by layers V-VI, and 
lowest in layer IV. This distribution was comparable to previous findings in rat brain using 
AChE and ChAT-histochemistry as cholinergic marker proteins (Wainer and Mesulam, 
1990).  
The young 4-month-old transgenic mice displayed no transgene-related changes despite of 
higher soluble Aβ production, and showed a similar cholinergic laminar distribution of 
VAChT density in S1BF, as compared to non-transgenic littermates. Developmentally, in 
wild type mice no significant differences in the global density of VAChT-immunoreactivity 
between young-adult and aged animals were found. However, in the cortex of 18-month-old 
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transgenic Tg2576 mice that demonstrated considerable Aβ burden and high levels of soluble 
Aβ peptides, the quantitative analysis of total VAChT-immunoreactivity revealed significant 
age-related regionally degradation and loss of cholinergic innervation in layers II/III and IV, 
as compared to corresponding values obtained in S1BF of younger transgenic mice. Our 
results compare well with a previous study in aged mice carrying familial AD-linked 
mutations, also demonstrating selective cholinergic denervation and decrease in number of 
ChAT-positive varicosities detected in hippocampus at 12/14 month-old and in the parietal 
cortex across different layers, at 18 months of age (Aucoin et al., 2005).  
 
4.4.3 VAChT expression: morphological and morphometric studies 
To reveal whether the transgene-mediated changes in VAChT-immunoreactivity are 
accompanied by morphological changes, morphometric studies of cholinergic afferents in two 
select cortical layers (II-III and IV) in S1BF were performed by determining fibre length and 
counting the number of boutons present in a particular fibre. For morphological 
characterization of cholinergic fibres high-power resolution of digital photomicrographs 
obtained from LSM microscope were used, which facilitated determination of varicosities 
present at cholinergic fibres.  
 
The detailed fine structural analysis of images showed that cholinergic fibres in tissue of aged 
transgenic and wild type mice have many swollen varicosities with larger in size compared to 
young animals, which was also observed in other studies on aging and in AD brains (see e.g., 
Nyakas et al., 2011). Moreover, cholinergic dystrophic neurites surrounding the plaque 
observed in S1BF of aged transgenic mice were endowed with numerous boutons being larger 
in size as normal, which is in agreement with a number of other studies (Onorato et al., 1989; 
Hu et al., 2003; Shi et al., 2009). Thus it has been proposed that abnormal accumulations of 
proteins and organelles within the swollen structures of cholinergic terminals point to the 
importance of axonal transport in AD (De Vos et al., 2008). It was also observed that the 
majority of cholinergic axon terminals in transgenic S1BF appeared to display a lower density 
of varicosities, which were distributed not homogeneously throughout the axonal profile, as 
compared to young animals. In general, the cholinergic terminals in S1BF of aged transgenic 
mice looked different to that observed in wild type tissue, presumably due to the action of Aβ.  
 
There is much debate and and support of the idea that major aspects of AD neuropathology 
are the result of failures in axonal transport. It has been demonstrated that the fast axonal 
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transport is inhibited by Aβ peptide oligomers, which further results in bidirectional axonal 
transport inhibition (Pigino et al., 2009). In particular, the axonal transport of vesicular ACh 
transporter (VAChT) was found to be inhibited by Aβ (Nyakas et al., 2011). Morover, Aβ (1-
42) promotes cholinergic dysfunction by triggering aberrant neuronal fibres sprouting, what 
may lead to reorganisation of morphological integrity of neuronal composition and might 
cause formation of fiber swelling forming grape-like structures (Masliah et al., 2003; 
Gaykema et al., 1992; see e.g., Nyakas et al., 2011). On the other hand, the aberrant neuritic 
sprouting may also be interpreted as an adaptive restorative response which subsequently 
turns into neuritic degeneration (Nyakas et al., 2011). Additionally, the chronic deterioration 
of intra-axonal transport capacity of cholinergic neurons and their cortical projections could 
promote the retrograde degeneration of the basal forebrain cholinergic fibres in case of AD 
(Nyakas et al., 2011). On the other hand, the reduction of microtubule-dependent axonal 
transport may stimulate pathological cleavage of APP resulting in Aβ deposition and plaque 
formation (Slotkin et al., 2005; see e.g., Nyakas et al., 2011). 
 
Our finding of a relative increase in the density of varicosities in aged transgenic Tg2576 
mouse brain compared to non-transgenic littermates suggests a role of Aβ in mediating 
neurodegenerative effects on cholinergic cerebral cortical fibre network, which is in 
agreement with many other studies (Wong et al., 1999; Hu et al., 2003; Klingner et al., 2003). 
Thus, in a number of other transgenic AD-like mouse models at early stages of amyloid 
pathology a significant plasticity of cortical cholinergic pre-synaptic VAChT-positive boutons 
by means of reorganization of the cholinergic network has also been observed. However, 
when comparing different transgenic AD-like mouse models a rather complex interaction 
between number and size of cholinergic synapses and AD-related mutated transgenes and 
amyloid burden has been found (Wong et al., 1999). E,g., transgenic mice expressing mutated 
human presenilin-1 (M146L) alone (with normal APP and no human amyloid generation) did 
not demonstrate any changes in the density of cholinergic synapses (Wong et al., 1999).  
It is interesting to note, that the significant elevation of density of VAChT-immunoreactive 
cholinergic synapses in Tg2576 mice occurred prior to plaque formation (Wong et al., 1999) 
and in aged mice with high plaque load (Klinger et al., 2003). The double mutant transgenic 
mice (hAPP/PS1), which have extensive amyloidosis, demonstrated a prominent diminution 
in the density of VAChT-immunoreactive synapses and reduction in the size these cholinergic 
synapses (Wong et al., 1999), presumably due to the synergistic effect of AD-related 
transgenes. Similarly, a negative correlation of plaque size and VAChT-positive cholinergic 
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density was observed in close proximity of plaques in doubly APP/PS1 transgenic mouse line 
(Hu et al., 2003). 
 
The quantitative morphometric analysis further demonstrated an age-related loss of 
varicosities on VAChT-immunoreactive fibres in layers II-IV of S1BF regardless of the 
transgeneity of the mice studied, with more severe reduction of VAChT-positive boutons in 
cortical layer IV. In previous neuropathological studies layers II and III are described to be 
more severe involved with AD pathological features than the deeper layers (Pearson et al., 
1985; Lippa et al., 1992; Gomez-Isla et al., 1996; see e.g., Romito-DiGiacomo et al., 2007). 
The neurons of the superficial layers are mainly involved in cortico-cortical connections 
whereas those in deeper layers project preferentially to non-cortical regions. In vitro studies 
have shown that the neurons in deeper cortical layers are more resistant to the toxic influence 
of Aβ(1–42), as compared to the neurons of the more superficial layers (Romito-DiGiacomo 
et al., 2007), hypothesizing that the differential regional vulnerability in AD depends on the 
extent of connectivity rather than on single neurons.  
Interestingly to note, that AChE is postulated to play also a non-enzymatic role in the 
development of neuritic projections (Slotkin et al., 2009). During brain development 
neurotransmitters serve important trophic functions that control neuronal cell replication and 
differentiation, synaptic organization, and morphologic assembly of brain nuclei (see e.g., 
Slotkin et al., 2009). There is ample evidence that ACh plays a role in structural and 
functional remodeling of cortical circuits (see review, Schliebs and Arendt, 2006). Also 
synaptic physiology and behavioral effects depend at least on molecular and/or structural 
changes in neuronal connections, as demonstrated previously for the somatosensory and 
visual cortex (see for review Hohmann, 2003). The cortico-cortical connections within rodent 
primary somatosensory cortex have been implicated as a major component involved in the 
rapid reorganization of cortical barrel maps. However, other investigators have suggested a 
role for subcortical structures in reorganization (see e.g., Arnold et al., 2001). Thus, layer IV 
receives a strong afferent input from ventroposterior thalamic projection neurons and any 
divergence in the thalamocortical projection to multiple cortical barrels could also provide an 
anatomical substrate for cortical plasticity and must be considered in any mechanism of rapid 
cortical reorganization (Arnold et al., 2001). During ontogenesis there is a great refinement of 
thalamo-cortical input to layer IV that underlies the maturation of its topographical map. 
Neonatal synaptic plasticity for NMDA- or kainite receptors and a rapid maturation in 
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GABAergic inhibition exhibit functional properties necessary for mature sensory processing 
(Daw et al., 2007).  
 
In conclusion, the data presented in this study provide further evidence, that age-related Aβ 
deposition alters the network of cholinergic connectivity, at least in the S1BF of transgenic 
Tg2576 mice. The alteration in neuronal synaptic plasticity in the aged transgenic mice under 
Aβ peptide overproduction may most likely be considered as compensatory mechanism in 
support of cholinergic neurotransmission. 
 
4.5 Age-related changes in cholinergic innervation of cerebral cortical 
microvessels in the presence and absence of β-amyloid plaque load 
 
In the present study, the mouse somatosensory cortex was representatively used to study the 
effect of β-amyloid on the cholinergic innervation of intracerebral microvessels in transgenic 
mice and non-transgenic littermates by applying semiquantitative dual immunohistochemistry 
of cholinergic terminals and blood vessels.  
 
4.5.1 STL – a mono-marker for detection of cortical vessels, senile amyloid 
plaques and activated microglia in cerebral cortex 
 
To differentiate between cholinergic terminals, intracerebral microvessels, and Aβ deposits in 
one and the same brain section, a lectin isolated from potatoes, the Solanum Tuberosum lectin 
(STL) has been tested for its usefulness in labeling blood vessels and Aβ. STL is homotypic 
endolectin that has carbohydrate-binding specificities to oligosaccharides, recognizing N-
acetyllactosamine-containing glycosphingolipids, may adhere to lactosylceramide (Gallagher 
1984; Ciopraga et al. 2000) and consists of two nearly identical chitin-binding modules (Van 
Damme et al., 2004).  
The STL-staining allowed the detection of cortical brain vessels in variable size, diameter and 
branches, from pial vessels covering the surface of the brain till intracortical capillaries, being 
in agreement with a previous study (Härtig et al., 2009). The comparison of Aβ staining 
pattern with other Aβ staining procedures by means of Thioflavin S dye and 
immunohistochemistry with the monoclonal antibody 4G8 revealed that STL labels both 
diffuse and fibrillar Aβ in brain sections that were not pretreated with formic acid. Moreover, 
STL may also be used to label glial cells and macrophages (Härtig at al., 2009). In order to 
reveal which kind of glia (micro-or astroglial cells) is stained by STL, brain sections were 
subjected to either immunostaining with anti-CD11b antibody, that labels microglial cells, or 
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glial fibrillary acidic protein (GFAP, that labels astroglial cells), and in each case 
counterstained with STL. While STL fluorescence was not co-localized with 
immunoreactivity for astroglial cells, STL was shown to label activated microglial cells.  
 
In conclusion, STL can be used to label brain cortical vessels, senile amyloid plaques and 
activated microglia. Moreover, it represents an adequate dye to be used in combination with 
other immunohistological markers. 
 
4.5.2 Cholinergic perivascular innervation of cerebral cortical microvessels in 
transgenic Tg2576 mice 
 
For a more detailed determination of cholinergic perivascular nerve terminals in the cerebral 
cortex of 8-month-old transgenic mice, high power Laser scanning microsopy by three-
dimensional (3D)-scanning (series of the multi-slice 2D-imaging along the z-axis) of double-
stained sections for VAChT and STL was used. This technique allows a more detailed 
description of the distribution of perivascular cholinergic terminals around blood vessels, its 
association with surrounding blood vessels of varying sizes in different cortical layers (see 
Fig. 3.19), and to spatially reconstruct perivascular cholinergic innervations (see Fig. 3.20). 
The high power Laser scanning microsopy revealed the presence of VAChT-positive nerve 
fibres closely associated with and partly attached on the wall of large blood vessel. The 
cholinergic nerve fibres appeared to overlay the vessel wall, or being apposed directly to the 
wall, and located within the immediate vicinity of small microvessels, being in agreement 
with a number of other histochemical and ultrastructural studies. Already few decades ago 
cholinergic nerve terminals have been reported to be present in direct vicinity of cortical 
microvessels (Eckenstein and Baughman, 1984; Armstrong, 1986; Arnerić et al., 1988). 
Perivascular AChE-positive nerve fibers at cerebral blood vessels of different mammalian 
species as well as connections of ChAT-immunoreactive terminals with pial arteries and 
capillaries have been visualized by many investigators (Arnerić et al., 1988; Suzuki and 
Hardebo, 1993; Chédotal et al., 1994, Vaucher and Hamel, 1995; for overview, see El-
Assouad and Tayebati, 2002). Revealed by co-staining of rat cortical brain section for 
Phaseolus vulgaris leucoagglutinin (PHA-L, anterogradely transported from cholinergic cells 
in the substantia innominata), and for ChAT-immunoreactivity, Vaucher and Hamel (1995) 
showed that cortical arterioles and capillaries receive a cholinergic input from cholinergic 
nuclei of the basal forebrain. Pharmacological and receptor autoradiographic studies provided 
evidence that endothelial and smooth muscle cells of cerebral vessels are endowed with a 
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number of transmitter receptors including different subtypes of the mAChRs (for review, see 
Hamel, 2004), suggesting a role of neurovascular projections originating from local 
interneurons, or from distant nuclei, to modulate cerebral blood flow (for review, see 
Girouard and Iadecola, 2006). 
 
In conclusion, the high power Laser scanning microscopy of brain sections co-stained for 
VAChT and STL as introduced in this study, represents a useful tool to study various aspects 
of the perivascular cholinergic network in mouse brain.  
 
4.5.3 Quantitation of cholinergic input on cerebral microvessels of mouse brain 
 
The evaluation of age-related immunohistochemical detection of blood vessels and 
cholinergic nerve terminals in the somatosensory cortex of Tg2576 mice and non-transgenic 
littermates provided evidence of Aβ plaque-mediated changes in densities of blood vessels 
and cholinergic fibres. Therefore the question arose whether the age-related Aβ production 
and deposition also have consequences on the morphological integrity of the neurovascular 
unit, in particular on the specific cholinergic innervation of blood vessels.  
Brain sections of the somatosensory cortex of 6- and 8-month-old transgenic Tg2576 mice, 
displaying enhanced level of soluble Aβ but not yet any plaque deposition, and of 18-month-
old transgenic animals with high plaque load were subjected to dual immunofluorescent 
histochemistry for both cholinergic fibres and blood vessels followed by quantitation of 
cholinergic contacts on microvessels using high power Laser scanning microscopy. 
 
Evaluation of cholinergic contacts/endings on microvessels within a length of 100 μm in 
somatosensory cortical sections of 6- and 8-month-old mice did not show any transgene-
mediated changes in cholinergic innervation of microvessels. However, further postnatal 
development of Tg2576 mice up to the age of 18 months resulted in a significant loss of 
cholinergic innervation of blood vessels in almost all cortical layers (except layer VI). Similar 
reductions of cholinergic contacts with microvessels were also observed in the somatosensory 
cortex of 18-month-old wild type mice, but restricted to cortical layers I and V, and being less 
severe as compared to that found in Tg2576 mice. 
 
In 6- and 8-month-old mice the number of varicosities (boutons) and length of microvessels 
did not differ between transgenic and wild type mice, while an impaired vascular 
autoregulation has been observed in transgenic APP mice (Kalaria, 2009). Moreover, the 
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earliest abnormality observed in these mice is a profound alteration in the cerebro-vascular 
regulation at 2–3 months of age (Iadecola, 2004), which correlates with behavioral 
abnormalities (Hsiao et al., 1996). Other studies in Tg2576 mice revealed cognitive 
impairments at the age of 6 months, before significant Aβ deposition (Westerman et al., 
2002).  Presumably, the beginning of disease-induced cerebral vascular alterations lead to 
mild disturbancies in regulation of cerebral blood flow, which are still not so severe to be 
detectable at the morphological level. 
 
The changes we have observed in the cerebral neurovascular cholinergic pathway in layers I 
to V of somatosensory cortex of 18-months old transgenic mice in comparison to younger 
transgenic animals, are in agreement with data obtained from other animal studies. Hamel and 
co-workers (2005) showed in 12 to 18-month old mice carrying familial AD-linked 
mutations, a selective cholinergic denervation of ChAT-positive varicosities, which initially 
started in the hippocampus by the age of 12-14 months and then reached the parietal cortex at 
the age of 18 months (Aucoin et al., 2005). However, despite decreased cholinergic cortical 
innervation there was no evidence of dystrophic cholinergic varicosities or significant loss in 
the perivascular area (Aucoin, et al., 2005), which may partly be explained by the different 
method of detection and quantification of neurovascular connections. However, the data 
obtained from studies in AD patients also support the results we have observed in Tg2576 
mice in the present study (Scheibel et al., 1987 and 1988; Tong and Hamel, 1999). Thus, 
structural analysis of the capillary plexus in brains of AD patients demonstrated perivascular 
denervation, and microangiopathy, which may be due to changes in capillary wall structure, 
with the consequence of leading to profound alterations in blood-brain barrier function 
(Scheibel et al., 1987 and 1988). Tong and Hamel (1999) showed regional denervation of 
intracortical microvessels and reduced nitric oxide synthase (NOS)-containing neurons with 
paralleled loss of total cholinergic nerve terminals in the corresponding areas of the cerebral 
cortex in neuropathologically confirmed cases of AD in comparison to age-matched control 
individuals (Tong and Hamel, 1999). The authors showed also dysfunctional interactions 
between basalo-cortical and intracortical NOS-containing neurons in regulation of cortical 
perfusion following basal forebrain activation in AD (Tong and Hamel, 2000). Interestingly to 
note, selective destruction of the cholinergic nucleus basalis magnocellularis in the rabbit 
leads to the deposition of Aβ in and around cerebral blood vessels (Roher et al., 2000). The 
data suggest that cortical cholinergic deprivation may result in the loss of vasodilation 
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mediated by ACh and may lead to cerebral hypoperfusion and a disruption of blood-brain 
barrier. 
 
Surprisingly, the changes in densities of cholinergic varicosities on cortical microvessels 
detected in the somatosensory cortex of 18-month-old Tg2576 mice did not correlate with 
plaque-load, which was also found in another animal study (Aucoin et al., 2005). The authors 
also did not find a direct relationship between the age-dependent increase in the number of 
plaques and the decrease in the density of ChAT-positive axonal varicosities in hippocampus 
and parietal cortex (Aucoin, et al. 2005). Therefore, they proposed non-selective and focal 
neurotoxic effects on cholinergic axons, assuming that plaque- and oxidative stress-
independent diffuse cholinotoxicity, most likely caused by soluble Aβ assemblies, is 
responsible for the hippocampal and cortical cholinergic denervation (Aucoin et al., 2005). 
While senile plaques in the AD brain have been believed for a long time to be the most toxic 
forms responsible for cholinergic neurodegeneration, there is now strong evidence that 
soluble oligomers of Aβ, such as low-molecular weight monomers, oligomers and amyloid-
derived diffusible ligands, as well as protofibrils ensure neurotoxic species that mediate early 
neuronal dysfunction and initiate neurodegeneration at cholinergic terminals (Lue et al., 1999; 
McLean et al., 1999; Klein et al., 2001; Hardy and Selkoe, 2002; Auld et al., 2002; Yan and 
Feng, 2004; for reviews, see Walsh and Selkoe, 2007; Schliebs and Arendt, 2011). These 
findings fit with observations that the severity of neurodegeneration in AD correlates best 
with the pool of soluble Aβ rather than with the number of insoluble Aβ plaques (McLean et 
al., 1999). As soluble Aβ(1-42) have the capacity to bind with high affinity to alpha7 nicotinic 
acetylcholine receptor (α7nAChR; Wang et al., 2000), and thereby suppressing the 
neuroprotective properties of α7nAChR, the blockade of α7nAChR by Aβ(1-42) may 
represent a potential mechanism to explain the cholinergic denervation of microvessels in the 
absence of any plaques in Tg2576 mouse brain. Moreover, there are other reports that Aβ(1-
42) may trigger cholinergic dysfunction by promoting aberrant neuritic sprouting (Masliah et 
al., 2003; Masliah et al., 1991).  
 
Changes in the cerebrovasculature and the related cholinergic input have also been observed 
in normal non-transgenic mice even though to a lesser extent as compared to Tg2576 animals, 
indicating that also normal physiological aging is accompanied by functional and structural 
decline of cholinergic transmission. The functional cholinergic decline associated with normal 
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aging may be the result of decrements in “cholinergic” gene expression, impairments in 
intracellular signaling, and cytoskeletal transport (for review, see Schliebs and Arendt, 2011).  
The aging-related alterations in densities of microvessels and cholinergic fibres found in the 
somatosensory cortex of 18-month-old wild type mice compare well with previous 
morphological studies. Kalaria (1996) described variable age-related changes in the 
perivascular nerve plexuses of both extraparenchymal and intracerebral vessels, but aging 
process is regionally selective and does not equally affect the perivascular innervation of CNS 
vessels (Kalaria, 1996). Burnstock and co-workers reported on age-related changes of 
perivascular cerebrovascular nerves with reduced expression of vasodilator nerves and an 
increased expression of vasoconstrictor nerves in the brain of old rats (Mione et al., 1988), 
whereas marked reductions in the noradrenergic and ACh-positive innervation of the middle 
cerebral arteries in aged rabbits have been shown (Saba et al., 1984). Another report 
demonstrated alterations in perivascular cholinergic nerve fibres with slight decrease in 
choline accumulation and increase in ChAT activity in the major cerebral arteries of the 22-
month-old rats (Hamel et al., 1990). A microanatomical study demonstrated age-related 
decrease of cholinergic ACh-immunoreactive nerve fibres in pial and intracerebral arteries of 
adult or senescent rats (El-Assouad and Tayebati, 2002). Interestingly, Ypsilanti and co-
workers (2008) detected reduced lengths of hippocampal cholinergic ChAT-positive fibers in 
the aged rat brain with no change in number and size of ChAT-positive neurons (Ypsilanti et 
al., 2008).  
As cholinergic cells steadily require support by the cholinotrophic nerve growth factor (NGF), 
the maintenance of functional NGF production and signaling in the aged nervous system is of 
particular importance. There are reports of sprouting responses of perivascular axons 
associated with intradural blood vessels after intraventricular infusion of NGF in the adult rat 
brain (Isaacson et al., 1990). To maintain the sprouting perivascular axons a continueous 
supply of NGF is required, while the level of endogenous NGF, or other factors produced by 
the vascular target tissue, are not sufficient to maintain the newly formed axons (Isaacson et 
al., 1995). 
 
In conclusion, the detailed morphological and morphometric analysis of cortical perivascular 
cholinergic innervation in the somatosensory cortex of both transgenic Tg2576 and normal 
wild type mice revealed age-dependent alterations that are more severe in cortical tissue 
suffering of Aβ plaque pathology. 
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4.6 Summary and conclusions 
The present study was undertaken to elucidate whether the age-related Aβ production and 
deposition may affect the morphological integrity of cerebral microvessels, cholinergic 
terminals and their intracerebral neurovascular architectonics. We wanted to contribute to the 
question whether changes in cerebral vessels, cortical cholinergic denervation, Aβ formation 
and deposition are interrelated.  
To in vivo characterize the developmental relationship of amyloid formation and deposition, 
cortical cholinergic innervation and cerebrovascular abnormalities, transgenic Tg2576 mice 
that overexpress the Swedish double mutation of human APP, and demonstrate significant 
cerebral cortical deposition of Aβ plaques at ages from 9 months onwards, were considered as 
an appropriate animal model. Thus, transgenic Tg2576 mice at ages between 4 and 18 months 
were investigated in order to reveal any effect of both soluble Aβ and Aβ plaque deposits on 
maturation and morphological integrity of cerebral cortical capillaries, cholinergic terminals 
and their cerebral neurovascular relationship with each other.  
Using the somatosensory cortex as a representative region, serial cryocut sections, obtained 
from mice at ages ranging from 4 up to 18 months, were subjected to immunohistochemistry 
to label vascular endothelial cells (GLUT1 immunostaining), cholinergic nerve terminals 
(VAChT immunostaining) and Aβ plaques (Thioflavin S, and/or Solanum Tuberosum lectin 
staining), followed by a thorough quantitative evaluation of the age-related spatial 
relationship between cerebral cortical capillaries, amyloid plaques and cholinergic terminals, 
using computer-assisted image analysis. Moreover, high power Laser scanning microscopy of 
brain sections co-stained for VAChT (cholinergic nerve terminals), and Solanum Tuberosum 
lectin (STL; dye for cerebral vasculature) was used as tool to study various aspects of the 
perivascular cholinergic network in mouse brain.  
 
The density of blood vessels estimated in the somatosensory cortex of transgenic mice by 
anti-GLUT-1 immunohistochemistry did not differ to that obtained in wild type mice before 
onset of plaque deposition (younger than 12 months). However, in aged, 18-month-old 
Tg2576 mice, demonstrating high plaque loads, decreased blood vessel densities, particularly 
in layer IV of the somatosensory cortex, were observed. 
The density of cholinergic terminals estimated by evaluation of VAChT 
immunohistochemistry in somatosensory cortical sections of wild type mice did not change 
with aging regardless of the cortical layer examined, while in cortical layers II/III and IV of 
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somatosensory cortex of transgenic Tg2576 mice age-related decreases in cholinergic fibre 
densities were assessed.  
However, quantitative morphometric analysis demonstrated an age-related reduction in the 
number of varicosities on cholinergic fibres, particularly in layer IV, in both transgenic 
Tg2576 mice and non-transgenic littermates. 
Cholinergic innervation of microvessels in the somatosensory cortex decreased with aging in 
both Tg2576 mice and non-transgenic littermates, as revealed by estimating the ratio of the 
number of cholinergic vascular contacts and total length of blood vessel. There was no 
significant difference in the perivascular cholinergic innervation in areas that demonstrated 
significant plaque load and those with no plaque deposits regardless of the cortical layer 
examined.  
 
The data presented in this animal study add further evidence that Aβ, in addition to its well-
described neurotoxic effects, may also contribute to neuronal dysfunction through its actions 
on the cerebrovasculature.  
The detailed morphological and morphometric analysis of cortical perivascular cholinergic 
innervation in the somatosensory cortex of both transgenic Tg2576 and normal wild type 
mice revealed age-dependent alterations in the network of cortical cholinergic connectivity 
that are more severe in cortical tissue suffering of Aβ plaque pathology. 
The changes in densities of cholinergic varicosities on cortical microvessels detected in the 
somatosensory cortex of 18-month-old Tg2576 mice did not correlate with plaque-load, 
which was also found in another animal study (Aucoin et al., 2005). These findings fit with 
observations that the severity of neurodegeneration in AD correlates best with the pool of 
soluble Aβ rather than with the number of insoluble Aβ plaques. 
Taken together, the data obtained in this in vivo study strongly support an age-related 
interplay of Aβ accumulation, cholinergic dysfunction, and vascular impairments, while it still 
remains to be elucidated which processes play a causative role and which events are 
secondary. A potential mechanism is provided by the vascular hypothesis of AD: Aging-, and 
life-style-associated damages of the brain microvasculature may affect Aβ clearance and 
perivascular drainage, promoting cerebrovascular Aβ deposition, inducing partial loss of 
cholinergic vascular innervation and changes in vascular function, angiogenesis and VEGF 
upregulation with consequences on APP processing and Aβ accumulation. 
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Introduction 
The majority of patients suffering of Alzheimer’s disease (AD) demonstrates cerebral 
vascular changes and impaired regulation of cerebral blood flow, that have been assumed to 
play an important role in AD pathogenesis (vascular hypothesis of AD). There is strong 
evidence that both β-amyloid oligomeres and plaques contribute to vascular injuries and to 
functional impairments of the neurovascular unit. Vice versa, amyloid lesions can be triggered 
by hypertension and ischemic brain injury, while β-amyloid aggregates appear to have anti-
angiogenic properties. Damaged vascular endothelial cells produce and secrete the Vascular 
Endothelial Growth Factor (VEGF) which has been shown to favour β-amyloidogenesis by 
cells forming the neurovascular unit. Moreover, the physiological functions of cerebral 
microvasculature (vasodilation/-constriction) are controlled by basal forebrain cholinergic 
neurons. Injured blood brain capillaries may result in cholinergic denervation and retrograde 
cell loss. Cholinergic dysfunction may result in impaired cerebral blood flow with 
consequences on normal function of the neurovascular unit including processing of the 
amyloid precursor protein (APP).  
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Aim of study 
The present study was undertaken to elucidate whether the age-related β-amyloid production 
and deposition may affect the morphological integrity of cerebral microvessels, cholinergic 
terminals and their intracerebral neurovascular architectonics, and whether size or type of 
plaques play a role in this process. We wanted to contribute to the question whether changes 
in cerebral vessels, cortical cholinergic denervation, β-amyloid formation and deposition are 
interrelated.  
 
Experimental approach  
The availability of transgenic mice that produce human β-amyloid peptides from birth and 
progressively develop Alzheimer-like -amyloid deposits in the aged brain appears to be a 
unique experimental approach to address such questions. To in vivo characterize the 
developmental relationship of amyloid formation and deposition, cortical cholinergic 
innervation and cerebrovascular abnormalities, transgenic Tg2576 mice that overexpress the 
Swedish double mutation of human APP, and demonstrate significant cerebral cortical 
deposition of β-amyloid plaques at ages from 10 months onwards, were considered as an 
appropriate in vivo animal model. In this developmental study transgenic Tg2576 mice at ages 
between 4 and 18 months were investigated in order to reveal any effect of both soluble β-
amyloid and β-amyloid plaque deposits on maturation and morphological integrity of cerebral 
cortical capillaries, cholinergic terminals and their cerebral neurovascular relationship with 
each other.  
Using the somatosensory cortex as a representative region, serial cryocut sections, obtained 
from mice at ages ranging from 4 up to 18 months, were subjected to immunohistochemistry 
to label vascular endothelial cells (anti-glucose transporter 1 (GLUT1) immunostaining), 
cholinergic nerve terminals (anti-vesicular acetylcholine transporter (VAChT) 
immunostaining) and β-amyloid plaques (Thioflavin S, and/or Solanum Tuberosum lectin 
staining), followed by a thorough quantitative evaluation of the age-related spatial 
relationship between cerebral cortical capillaries, amyloid plaques and cholinergic terminals, 
using computer-assisted image analysis. Moreover, high power Laser scanning microscopy of 
brain sections co-stained for VAChT (cholinergic nerve terminals), and Solanum Tuberosum 
lectin (STL; dye for cerebral vasculature) was used as tool to study various aspects of the 
perivascular cholinergic network in mouse brain.  
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Results obtained 
The main results obtained in the study presented were as follows: 
 
1. Density of blood vessels estimated in the somatosensory cortex of transgenic mice by anti-
GLUT-1 immunohistochemistry did not differ to that obtained in wild type mice before onset 
of plaque deposition (younger than 12 months). However, in aged, 18-month-old Tg2576 
mice, demonstrating high plaque loads, decreased blood vessel densities, particularly in layer 
IV of the somatosensory cortex, were observed. 
 
2. The density of cholinergic terminals estimated by evaluation of VAChT 
immunohistochemistry in somatosensory cortical sections of wild type mice did not change 
with aging regardless of the cortical layer examined, while in cortical layers II/III and IV of 
somatosensory cortex of transgenic Tg2576 mice age-related decreases in cholinergic fibre 
densities were assessed.  
However, quantitative morphometric analysis demonstrated an age-related reduction in the 
number of varicosities on cholinergic fibres, particularly in layer IV, in both transgenic 
Tg2576 mice and non-transgenic littermates. 
 
3. Cholinergic innervation of microvessels in the somatosensory cortex decreased with aging 
in both Tg2576 mice and non-transgenic littermates, as revealed by estimating the ratio of the 
number of cholinergic vascular contacts and total length of blood vessel. There was no 
significant difference in the perivascular cholinergic innervation in areas that demonstrated 
significant plaque load and those with no plaque deposits regardless of the cortical layer 
examined.  
 
4. The high power Laser scanning microscopy of brain sections co-stained for VAChT, and 
STL represents a useful tool to study various aspects of the perivascular cholinergic network 
in mouse brain.  
 
Conclusions 
1. The data presented in this animal study add further evidence that β-amyloid, in addition to 
its well-described neurotoxic effects, may also contribute to neuronal dysfunction through its 
actions on the cerebrovasculature.  
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2. The detailed morphological and morphometric analysis of cortical perivascular cholinergic 
innervation in the somatosensory cortex of both transgenic Tg2576 and normal wild type 
mice revealed age-dependent alterations in the network of cortical cholinergic connectivity 
that are more severe in cortical tissue suffering of β-amyloid plaque pathology. 
 
3. The changes in densities of cholinergic varicosities on cortical microvessels detected in the 
somatosensory cortex of 18-month-old Tg2576 mice did not correlate with plaque-load, 
which was also found in another animal study (Aucoin et al., 2005). These findings fit with 
observations that the severity of neurodegeneration in Alzheimer’s disease correlates best 
with the pool of soluble β-amyloid rather than with the number of insoluble β-amyloid 
plaques. 
 
4. Taken together, the data obtained in this in vivo study strongly support an age-related 
interplay of Aβ accumulation, cholinergic dysfunction, and vascular impairments, while it still 
remains to be elucidated which processes play a causative role and which events are 
secondary. A potential mechanism is provided by the vascular hypothesis of AD: Aging-, and 
life-style-associated damages of the brain microvasculature may affect β-amyloid clearance 
and perivascular drainage, promoting cerebrovascular β-amyloid deposition, inducing partial 
loss of cholinergic vascular innervation and changes in vascular function, angiogenesis and 
VEGF upregulation with consequences on APP processing and β-amyloid accumulation. 
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